

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

A4

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>6</sup> :</b> <b>C12Q 1/68, C12P 19/34, C07H 21/04</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/23645</b> <b>(43) International Publication Date:</b> 3 July 1997 (03.07.97)
<b>(21) International Application Number:</b> PCT/US96/00362 <b>(22) International Filing Date:</b> 4 January 1996 (04.01.96) <b>(30) Priority Data:</b> Not furnished 22 December 1995 (22.12.95) US <b>(71) Applicant:</b> SLOAN-KETTERING INSTITUTE FOR CAN- CER RESEARCH [US/US]; 1275 York Avenue, New York, NY 10021 (US). <b>(72) Inventors:</b> YANG, Soo, Young; 444 E 75th Street, New York, NY 10021 (US). CEREB, Nezh; 1233 York Avenue #131, New York, NY 10021 (US). <b>(74) Agents:</b> LARSON, Marina, T. et al.; Oppedahl & Larson, Suite 309, 1992 Commerce Street, Yorktown Heights, NY 10598- 4412 (US).		<b>(81) Designated States:</b> CA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHODS AND REAGENTS FOR TYPING HLA CLASS I GENES  <b>(57) Abstract</b>  Consensus sequences of introns (1, 2 and 3) from the majority of HLA-A, -B and -C allotypes are identified and used to develop primers located within introns (1 and 3) of these genes. The primers are suitable for locus-specific amplification of the entirety of exons (2 and 3). These primers are also suitable for use as sequencing primers to determine the HLA alleles in sequence-based HLA typing. The primers can be used for amplification of portions of introns 1 or 3 and evaluating the amplified products to determine the allelic type of the HLA-A, HLA-B or HLA-C genes. Preferably, one of the primers has a sequence which provides locus-specific amplification.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

## METHODS AND REAGENTS FOR TYPING HLA CLASS I GENES

DESCRIPTION

This application relates to methods and reagents for typing HLA alleles of Class I genes.

The HLA Class I genes are a component of the human major histocompatibility complex (MHC). The Class I genes consist of the three classical genes encoding the major transplantation antigens HLA-A, HLA-B and HLA-C and seven non-classical class I genes, HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-K and HLA-L.

The classical HLA Class I genes encode polymorphic cell surface proteins expressed on most nucleated cells. The natural function of these proteins is to bind and present diverse sets of peptide fragments from intracellularly processed antigens to the T cell antigen receptors (TCRs). Thus, the peptide-binding capability of the MHC molecule facilitates immune recognition of intracellular pathogens and altered self proteins. Therefore, by increasing the peptide repertoire for TCRs, the polymorphism of MHC molecules plays a critical role in the immune response potential of a host. On the other hand, MHC polymorphism exerts an immunological burden on the host transplanted with allogeneic tissues. As a result, mismatches in HLA class I molecules are one of the main causes of allograft rejection and graft versus host disease, and the level of HLA matching between tissue donor and recipient is a major factor in the success of allogeneic tissue and marrow transplants. It is therefore a matter of considerable medical significance to be able to determine the "type" of the HLA Class I genes of candidate organ donors and recipients.

HLA class I histocompatibility antigens for patient-donor matching are conventionally determined by serological typing. Biochemical and molecular techniques have revealed that HLA class I polymorphism is far greater than previously recognized by conventional methods. To date, over 59 HLA-A, 127 HLA-B, and 36 HLA-C different allelic sequences have been identified. Bodmer et al., "Nomenclature for factors of the HLA system," *Tissue Antigens* 46: 1-18 (1995). This high level of allelic diversity complicates the typing of the HLA class I genes.

Another complicating factor is the large number of homologous genes and alleles. Each of the HLA Class I genes is composed of eight exons and seven introns as shown in Fig. 1, and the sequences of these exons and introns are highly conserved across the HLA

- 2 -

Class I genes. Allelic variations mostly occur in exons 2 and 3 which are flanked by noncoding introns 1, 2, and 3. These two exons encode the functional domains of the molecules.

5 Taken together, these two complications make HLA Class I typing at the nucleic acid level a formidable task. Allelic diversity within any one gene means that a great many probes need to be developed if hybridization-based tests are used in the typing. Further, the general applicability of DNA typing methods to HLA Class I genes depends on the design of primers which provide effective locus-specific amplification of exons 2 and/or 3 of one HLA Class I gene.

10 One method for performing HLA Class-I typing is disclosed in US Patent No. 5,424,184 which is incorporated herein by reference. This patent utilizes primers which are located within exons 2 and 3 of the HLA Class-I genes to achieve what is described as group-specific amplification of a portion of the HLA-A, HLA-B and HLA-C genes. This approach is not ideal, however, since the primers hybridize with portions of the coding strand, and thus may mask significant allelic variations. In addition, this method requires a grouping of alleles by means of another method in order to select group-specific primers for amplification.

15 In assessing the known exon 2 and 3 sequences found in the HLA class I sequence database (Arnett & Parham, *Tissue Antigens* 46: 217-257 (1995)), there is only one possible HLA-A locus-specific primer site located in exon 2. (Oh et al., *Tissue Antigens* 41: 135-142 (1993)) Using a primer for this site, HLA-A locus-specific amplification produced a PCR product of 671bp, containing a portion of exon 2, intron 2, and exon 3. This amplified DNA fragment does not contain the first variable region of HLA-A the molecule. In addition, the primers are not entirely specific and lead to amplification of some HLA-H alleles. Thus, locus-specific amplification using this primer does not provide a highly effective method for typing HLA-A genes.

25 Similar evaluations of the known exon sequences (Arnett and Parham, *supra*) showed that there are no suitable primer sites for the HLA-B genes. For HLA-C alleles, two separate sets of primers are needed to amplify both exon 2 and 3. (Levine and Yang, *Tissue Antigens* 44: 174-183 (1994). Universal primers designed for exons 2 and 3 also amplified

30

- 3 -

the non-classical genes. Exon 4 contains locus-specific sequences but it is separated by  $\approx 590$ bp from exon 3, making exon 4 an impractical PCR primer site.

Thus, there remains a real need for locus-specific primers for the HLA class I genes to provide amplified materials for use in class I typing by PCR-DNA methods (e.g. Sequencing-, SSO-, and SSP-based). It is an object of the present invention to provide methods and reagents effective to provide locus-specific amplification of the HLA Class I genes.

It is a further object of the present invention to provide locus-specific primers amplification primers which hybridize with the introns flanking exons 2 and 3 of the major transplantation antigens.

It is still a further object of the present invention to use these primers to achieve locus-specific amplification which is an essential step in developing a DNA-based HLA class I typing methodology.

#### SUMMARY OF THE INVENTION

We have determined the sequences of introns 1, 2 and 3 from the majority of HLA-A, -B and -C allotypes and from alleles of HLA-E, -F, -G, -H, -J, -K, and -L. From these intron sequences, we have now developed primers located within introns 1 and 3 of the HLA-A, HLA-B and HLA-C genes. These primers are suitable for locus-specific amplification of the entirety of exons 2 and 3, i.e., the portion of these of genes most suitable for use in typing of HLA-A, HLA-B and HLA-C. These primers are also suitable for use as sequencing primers to determine the HLA alleles in sequence-based HLA typing. Thus, in accordance with the invention, there is provided a method for testing a sample to determine the HLA-A, -B or -C type of the sample comprising the steps of

- (a) treating the tissue sample to obtain nucleic acid polymers suitable for amplification;
- (b) combining the nucleic acid polymers with a first primer which is complementary to a portion of intron 1 of the HLA gene, and a second primer which is complementary to a portion of intron 3 of the HLA gene under conditions suitable for amplification to obtain an amplified product; and
- (c) evaluating the amplified product to determine the allelic type of the HLA-A, HLA-B or HLA-C genes. This evaluation step can make use of any of the known methods

- 4 -

for nucleic acid-based typing of HLA genes, including direct sequencing, sequence-specific oligotyping (SSO) or sequence-specific primer amplification (SSP) of the amplified products. Preferably, at least one of the amplification primers has a sequence which provides locus-specific amplification.

5 In addition, we have identified primers which provide locus-specific amplification for HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-K and HLA-L. Thus, there is also provided a method for testing a tissue sample to determine the HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-K and/or HLA-L type of the sample comprising the steps of

(a) treating the tissue sample to obtain nucleic acid polymers suitable for amplification;

10 (b) combining the nucleic acid polymers with a first primer which is complementary to a portion of exon 2 of the human major histocompatibility complex, and a second primer which is complementary to a portion of exon 3 of the human major histocompatibility complex under conditions suitable for to obtain an amplified product; and

(c) evaluating the amplified product to determine the allelic type of the HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-K and HLA-L genes. This evaluation step can  
15 make use of sequence-specific oligotyping, PCR-SSOP-based typing or can involve direct sequencing the amplified products.

#### BRIEF DESCRIPTION OF THE DRAWINGS

20 Fig. 1 shows the organization of the eight exons and seven introns of an HLA Class I gene;

Fig. 2 shows a consensus sequence for intron 1 of the classical HLA Class I genes with suggested primer locations;

Fig. 3 shows a consensus sequence for intron 2 of the classical HLA Class I genes with  
25 suggested primer locations;

Fig. 4 shows a consensus sequence for intron 3 of the classical HLA Class I genes with suggested primer locations;

Figs. 5A-5H shows individual aligned sequences determined for each intron;

Fig. 6 shows the sequences of exon 2 of the non-  
30 classical HLA Class I genes;

Fig. 7 shows the sequences of exon 3 of the non-classical HLA Class I genes; and

Fig. 8 shows the name and allelic type of 106 cell lines tested using the amplification primers of the invention.

#### DETAILED DESCRIPTION OF THE INVENTION

5       The present invention relates to methods for typing tissue samples to determine the HLA Class I type of the sample. Thus, a first embodiment of the invention is a method for testing a tissue sample to determine the HLA-A, HLA-B or HLA-C type of the sample comprising the steps of

(a) treating the tissue sample to obtain nucleic acid polymers suitable for amplification;

10       (b) combining the nucleic acid polymers with a first primer which hybridizes with a portion of intron 1 or intron 3 of the HLA-gene being tested, and a second primer which hybridizes with a different portion of the HLA-gene being tested under conditions suitable for nucleic acid amplification to obtain an amplified product; and

15       (c) evaluating the amplified product to determine the allelic type of the HLA-A, HLA-B or HLA-C genes. Preferably, at least the first amplification primer is one which specifically hybridizes to only one type of HLA Class I gene, so that locus specific amplification is achieved.

20       Figs. 2, 3 and 4 shows combined sequences (Seq. ID Nos.: 1-9) for introns 1, 2 and 3 respectively, together with suitable locations for binding amplification primers. These sequences are consensus sequences derived from the individual aligned sequences determined for each intron as shown in Figs. 5A-5H. In these sequences, bases which are the same for the locus across the various strains tested are indicated as a single base (A, C, G or T), while bases which were variable in the strains tested are indicated by a code for alternative bases. In general, it will be advantageous to select primers to avoid the variable  
25       bases, although in some of the primers discussed below, intra-locus variation is taken into account.

The method of the invention can be performed on whole blood, tumor cells, sperm, hair follicles or any other nucleated tissue sample.

30       Once the sample is obtained, the next step is to treat the tissue sample to obtain nucleic acids for amplification. Genomic DNA preparation suitable for amplification can be obtained by proteinase K digestion, as previously described in Levine et al., *Tissue Antigens*

- 6 -

44: 174-183 (1994). Briefly, this method involves removal of red cells in the case of blood samples after lysing by a hypotonic solution and then the remaining white cells are treated with Proteinase K in a detergent-containing solution to release DNA from nuclei and digest proteins in the cell lysate. After inactivation of the proteinase K, the remaining DNA in the solution is used as an amplification template. Other methods for preparing genomic DNA which may also be used in accordance with the invention include salting-out extraction procedures (Miller S, Dykes D, and Polesky H., "A simple salting out procedure for extracting DNA from human nucleated cells" Nucleic Acids Res. 16: 1215, 1988) and the standard phenol-chloroform DNA extraction procedure (Current Protocols in Molecular Biology, Series ed. K. Jansson, Wiley Interscience).

Once the sample has been treated, it is combined with two amplification primers and amplified, for example using Polymerase Chain Reaction (PCR) amplification. The basic process of PCR amplification is known, for example from U.S. Patents Nos. 4,683,202 and 4,683,195, which are incorporated herein by reference. In PCR amplification, two amplification primers are used, each of which hybridizes to a different one of the two strands of a DNA duplex. Multiple cycles of primer extension, and denaturation are used to produce additional copies of DNA extending from the position of one primer to the position of the other. In this way, the number of copies of the genetic material positioned between the two primer binding sites is increased.

In the present invention, amplification of exons 2 and 3 is preferably performed using at least one locus-specific primer which specifically hybridizes to a portion of intron 1 or intron 3. As used in the specification and claims hereof, the primers which "specifically hybridize" to the introns are primers which permit locus-specific amplification by having a sequence which is exactly complementary to the expected sequence of a portion of the intron so that binding and amplification can occur, but which is not complementary to a region on any of the other HLA Class I genes. It will be understood that locus-specific primers within the scope of this invention need not be complementary to a totally unique sequence within the human genome, provided that both members of the primer pair used in amplification do not bind to the same gene outside the gene of interest.

The second amplification primer is preferably one which hybridizes with the other flanking intron (i.e., intron 3 when the first primer hybridizes to intron 1 and vice versa),



- 7 -

since this will result in the simultaneous amplification of both exons 2 and 3. It will be appreciated, however, that exons 2 and 3 could be amplified individually by selecting a second amplification primer for exon 2 and a first primer for exon 3 which hybridize with intron 2 (Seq. ID Nos.: 2, 5 and 8), and such amplifications are within the scope of the invention.

Amplification primers useful in the present invention are generally from 10 to 40 bases in length, more preferably from 21 to 35 bases in length. Within this size range, we have identified suitable locus-specific, group specific and allele-specific primers for each of the classical HLA Class I genes.

For locus-specific amplification of the HLA-A gene, suitable locus-specific primers have the sequence

GGCCTCTGYG GGGAGAAGCA A

SEQ ID NO.: 10

or

GAAACSGCCT CTGYGGGGAG AAGCC

SEQ ID NO.: 11

Degenerate bases can be introduced in the primer sequences where alternative bases occur among alleles. These primers are complementary to the region of the non-coding strand spanning nucleotides 26-46 and 21-45, respectively of the intron 1 sequence shown in Fig. 2 (Seq. ID No.: 1). It will be appreciated that this primer could be made longer by adding additional complementary bases to the 5'-end. The primer might also be made somewhat shorter, for example spanning nucleotides 26-44, since nucleotides 23, 24 and 25 are identical across the various HLA-locuses in sequences of which the inventors are aware. In addition to primers binding to the non-coding strand, it will be appreciated that complementary primers which bind to the corresponding portions of the coding strand could be used with a compatible second primer. The use of longer or shorter locus-specific primers, and of complementary locus-specific primers are within the scope of the present invention.

Locations of these and additional primers within each of introns 1, 2, and 3 are shown in Figs. 2, 3 and 4.

An amplification primer which binds to the non-coding strand of the HLA-A gene is used in combination with a second amplification primer which binds to the coding strand to achieve locus specific amplification. Preferably, both primers will be locus-specific in their

- 8 -

hybridization to the HLA gene, although to achieve locus specific amplification only one of the two primers used to amplify DNA from the sample is required to be a locus-specific primer. Examples of locus-specific amplification primers which bind to the coding strand of the HLA-A gene include

5 CGGGAGATCT AYAGGCGATC AGG SEQ ID No.: 12,  
TGTTGGTCCC AATTGTCTCC CCTC SEQ ID No.: 13, and  
AGGATTCCTC TCCCTCAGGA CCA SEQ ID No.: 14.

These primers bind to the region of the coding strand of intron 3 of the HLA-A gene (SEQ ID No.: 3) spanning nucleotides 25-47, 65-88 and 108-131, respectively, as shown in Fig.

10 4. As in the case of the first amplification primer, amplification primers which are a made a few bases longer by virtue of adding additional complementary bases, amplification primers which are a few bases shorter, and complementary amplification primers may be used in the method of the present invention. Other potential sites for HLA-A locus specific primers are highlighted in Fig. 4.

15 The amplification primers and the genomic DNA are combined in an amplification mixture, for example containing 10 to 100 ng of genomic DNA in a 100  $\mu$ l volume containing 0.2 mM dNTPs, the two primers at a concentration of 0.2  $\mu$ M each, 2.5 units of Taq polymerase, 50 mM Tris-HCl (pH 8.8), 50  $\mu$ M EDTA, 1.5 mM  $MgCl_2$ , 0.01% (w/v) gelatin, 10 mM  $\beta$ -mercaptoethanol and 10% (w/v) DMSO. The mixture is denatured at a  
20 temperature of 96°C of 5 minutes. Multiple cycles, for example thirty cycles, of amplification are then performed. For HLA-A, -B and -C a suitable cycle program is

denaturation	94°C	22 seconds
annealing	65°C	50 seconds
extensions	72°C	30 seconds.

25 Different cycling conditions may be used to obtain good PCR yields from longer or shorter primers.

While PCR amplification is the preferred approach to amplification of the treated sample, other techniques which use oligonucleotide primers to define a region of DNA to be amplified can be used as well. Such techniques include ligase chain reaction  
30 amplification (Wiedmann et al., PCR Primer, Laboratory Manual, Cold Spring Harbor (1991)).

- 9 -

The amplification procedure results in the production of an amplified product, in which the region of the HLA-A gene between the two primers is significantly increased in concentration relative to other genetic material in the treated sample. The amplified product is then evaluated to determine the allelic type of the HLA gene. This evaluation step can utilize any procedure which results in identification of allelic type.

For example, the amplification product can be evaluated by hybridization with locus-specific, group-specific or allele-specific oligonucleotide probes. Probes of this type which bind to the HLA-A gene are known in the art, for example from Oh et al., *Tissue Antigens* 41: 135-142 (1993) and Bugawan et al., *Tissue Antigens* 44: 137-147 (1994).

Oligonucleotide probes can be used in any of a number of test formats. For example, a dot blot analysis can be performed as described in Examples 1-3 below. Briefly, in this analysis the amplified product is affixed to a solid support in an array of dots. Labeled probes of different types are then applied to the dots. After washing to remove unhybridized probes, each dot is evaluated for the presence of hybridized (bound) probe using the label.

Other hybridization test formats may also be used. For example, the amplification primers used may be labeled with a detectable label, e.g., a radiolabel, a colored or chromogenic label, or a fluorescent or fluorogenic label; or an immobilization moiety such as a biotin. The probes are then labeled with a complementary type of label, i.e., immobilizing when the amplification primers have a detectable label, and a detectable label when the amplification primers are immobilizable. The probes and the amplification products are combined under hybridizing conditions before or after immobilization of the immobilizable component of the reaction on a solid support, and the capture of the labeled component onto the solid support is monitored. Suitable solid supports include chromatographic columns and magnetic beads. Specific examples of suitable probes are listed in Table 1.

The amplification product may also be evaluated using direct sequencing as described in Santamaria et al., *Hum. Immunology* 37: 39-50 (1993). The amplified product can be sequenced using the well-known dideoxy chain termination method. Briefly, in this method a sequencing primer complementary to one strand of the amplified product is combined with the amplified product, a template-dependent polymerase enzyme, a mixture of the four standard nucleotide bases (A, G, T, and C) and one type of dideoxy nucleotide base. The

TABLE I

SEQ ID No.	Probe *noncoding	Sequence	First Codon Pos.	Specificity
62	131R	CGCTCTTGGA CCGCG	131	A, L
63	HBB034	GTTCGTGAGG TTCGACAGC	32	B
64	HYB035	CGCCGTGGGT GGAGCAGGA	49	B*5401, C, G, L
65	EE2-210	GCACAGACAC GGAACACC	71	E
66	FE2-200*	GTCTGTCTGT TGGCCTTG	67	F
67	GE2-183	GAGGAGACAC GGAACACC	62	G, L
68	HE3-479*	TCCACGAACT CGCCTCC	158	H
69	JE3-274*	TTCCCTGGAG GATGTGAT	92	J, K
70	HLB032	CAGCGACTCC GTGAGTCCG	37	L
71	142IK	CAGATCACCA AGCGC	141	A1, A3, A11, A24, A36, H
72	114EH	TATGAACAGC ACGCC	113	A30, H
73	HXC008	CTGCGGATCG CGTCCGCT	78	A23, A24, A25, A32, B*2702, B38, B49, B51, B52, B53, B17, H
74	HBB055	CCGCGAGTCC GAGGATGGC	40	B15, B46, B57, E
75	HBC009	CTGCGGACCC TGCTCCGCT	78	B27, B37, B47, J, K, L
76	HYE024	GGACCTGCCG TCCTGGACC	128	B7, B8, B*2707, B40, B41, B42, B*4801, all Cw's except Cw3, Cw4, and Cw14, E, F, G, H, J, K, L
77	HBD080	CGGGTACCAC CAGGACGCC	111	B27, B47
78	HBD083	CGGGTATGAC CAGGACGCC	111	B44
79	HBD086	CGGGTATAAC CAGTTAGCC	111	B45, B49, B50
80	HBFO94	GACAAGCTGG AGCGCGCTG	177	B7, B*4001, B*4802
81	HBC065	GAAGTACAAG CGCCAGGCA	65	B46
82	HBC066	GAACATGAAG GCCTCCGCG	65	B57, B58
83	156R	GCGGAGCAGC GGAGAGCC	153	B7, B*3508, B*5702, Cw1, Cw*0401, Cw*0802, Cw14

- 11 -

bases are added to the end of the amplification primer to form a new oligonucleotide complementary to the amplification product. When a dideoxy base is added, however, no additional bases can be added. This results in the formations of a family of oligonucleotides whose lengths reflect the positions of the nucleotide base provided in dideoxy form within the complementary oligonucleotide. By evaluating the fragments formed in four reactions mixtures, one for each type of dideoxy nucleotide base, by gel electrophoresis, the sequence of the complementary strand can be deduced.

Basic procedures for performing nucleic acid sequencing in this manner are well known in the art, and commercial instruments are available for this purpose. Thus, sequencing is a routine procedure provided that amplified DNA and suitable primers are available. In this case, the same primers used to amplify the DNA can be used as sequencing primers.

Nested intron primers can also be used as sequencing primers. These primers are complementary to the sequences of the amplified products located in intron 1, intron 2 or intron 3 (SEQ ID Nos.: 1-9). It is particularly advantageous to have "universal" sequencing primers which could be used in the sequencing of any of the major transplantation antigen genes after locus-specific amplification, and such primers are an aspect of the present invention.

Examples of universal primers for sequencing the non-coding strand of the exon 2 which are complementary to the non-coding strand of intron 1 include:

GGGTCKGKYR GRTYTCAGC SEQ ID No.: 15

and

CGCSCMKGGA SGWGGGTC SEQ ID No.: 16.

These primers are complementary to the portion of intron 1 spanning nucleotides 95-113 and 82-99, respectively.

An example of a universal primer for sequencing the non-coding strand of the exon 2 which is complementary to the non-coding strand of the exon 2 is

TCYCACTCCA TGAGGTATTT C SEQ ID No.: 17.

This primer is complementary to the portion of exon 2 spanning nucleotides 3-23.

Examples of universal primers for sequencing of the coding strand of the exon 2 which are complementary to the coding strand of intron 2 include:

- 12 -

GGCYGGGGTC ACTCACCG

SEQ ID No.: 18

and

GTCSTGACCT SCGCCCC

SEQ ID No.: 19.

These primers are complementary to the portion of intron 2 spanning nucleotides -2 to 15 and 19-35, respectively.

Examples of universal primers for sequencing of the non-coding strand of the exon 3 which are complementary to the non-coding strand of the intron 2 include:

GCGGGRCGGG GCTCGGGGG

SEQ ID No.: 20

and

ATYCCCSCRG KTTGGTC

SEQ ID No.: 21.

These primers are complementary to the portion of intron 2 spanning nucleotides 214-236 and 194-210, respectively.

An example of a universal primer for sequencing of the coding strand of the exon 3 which is complementary to the coding strand of the intron 3 is

CCCYRYKGCC CCTGGTAC

SEQ ID No.: 22.

This primer is complementary to the portion of intron 3 spanning nucleotides 1 to 18.

Other potential sequencing primer sites are highlighted in Figs. 2, 3 and 4. In addition, the primers disclosed in US Patent No. 5,424,184 for sequencing of the HLA-A locus may also be used.

The amplified DNA products may also be evaluated by agarose gel electrophoresis for typing HLA alleles, for example using the techniques described in Browning et al., *Hum. Immunology* 39: 143 (1994); Krausa et al., *Lancet* 341: 121-122 (1993). Briefly, in this method each group of alleles or individual allele is amplified by a group-specific or an allele-specific primer pair exactly matched to that group or allele. By keeping the PCR conditions stringent, the primer pairs will not non-specifically amplify other related alleles. The amplification primers are designed with the specificity-dependent nucleotide(s) on the terminal 3'-prime end. Identification of the alleles is based on the absence or presence of amplified products observed after agarose gel electrophoresis.

The same procedures described above can be used in accordance with the invention to determine the type of HLA-B and HLA-C genes in a sample. For typing the HLA-B gene, an exemplary locus-specific first amplification primer has the sequence

- 13 -

GGGAGGAGCG AGGGGACCSC AG

SEQ ID No.: 23

This amplification primer is complementary to the region of the non-coding strand spanning nucleotides 36-57 of the intron 1 sequence (Seq ID No.: 4) of the HLA-B gene shown in Fig. 2. Primers might also be derived from the di-allelic site spanning nucleotides 57-76, for example

CGGGGGCGCA GGACCCGG

SEQ ID No.: 24

or

GGCGGGGGCG CAGGACCTGA

SEQ ID No.: 25

which span nucleotides 59-76 and 57-76, respectively.

As in the case of the locus-specific primers for HLA-A, it will be appreciated that this primer could be made longer by adding additional complementary bases to either or both ends. The amplification primer might also be made somewhat shorter, for example spanning nucleotides 39-57 in the case of Seq ID No.: 23, since nucleotides 38, 39 are identical across the HLA-genes of which the inventors are aware, although this may result in the loss of some discrimination between HLA-B and HLA-C genes if nucleotide 37 (which is different in HLA-C genes from HLA-A and HLA-B) is not spanned by the probe. In addition, complementary amplification primers which bind to the corresponding portions of the coding strand could be used with a compatible second primer. The use of such longer or shorter primers and of complementary primers is within the scope of the present invention.

Exemplary locus-specific second amplification primers which can be used in typing the HLA-B gene using the method of the invention have the sequence:

GGAGGCCATC CCCGCGGACC T

SEQ ID NO.: 26,

and

GGAGGCCATC CCCGCGGACC TAT

SEQ ID No.: 27,

These primers bind to the region of the coding strand of intron 3 of the HLA-B gene (SEQ ID No.: 6) spanning nucleotides 38-58, 36-58, respectively, as shown in Fig. 4. As in the case of the first amplification primer, amplification primers which are made a few bases longer by virtue of adding additional complementary bases, amplification primers which are a few bases shorter, particularly those which span nucleotides 40-50, and complementary amplification primers may be used in the method of the present invention.

The primers

- 14 -

CTCAGGAAAA CTCATSCCAT TCTCCATTC AAG

SEQ ID No.: 28;

and

GGAGATGGGG AAGGCTCCCC ACT

SEQ ID No.: 29

which bind to the region of the coding strand of intron 3 of the HLA-B gene (SEQ ID No.: 6) spanning nucleotides 106-137 and 12-34, respectively, can also be used for amplification of the HLA gene, although this primer also amplifies HLA-C.

Other locus-specific, group-specific or allele specific oligonucleotides which are complementary to the non-coding strand of introns 1 and 2 of the HLA-B gene and which can be used in the method of the invention are indicated in Figs. 2 and 3. Similarly, other locus-specific, group-specific or allele specific oligonucleotides which are complementary to the coding strand of introns 2 and 3 of the HLA-B gene and which can be used in the method of the invention are indicated in Figs. 3 and 4. Any of these oligonucleotides can be used in combination the locus-specific primers for locus-specific amplification, although the use of two-locus specific amplification primers is preferred. These oligonucleotides can also be used as sequencing primers for typing of the HLA-B gene, although the universal primers described above (SEQ ID Nos.: 15-22) are preferred.

Suitable probes for use in hybridization assays of the type of the amplified product made using these primers are Ragupathi et al., *Tissue Antigens* 46: 24-31 (1995), Fernandez-Vina et al., *Tissue Antigens* 45: 153-168 (1995); and in Fleischhauer et al., *Tissue Antigens* 46: 281-292 (1995) and are listed in Table 1.

For typing the HLA-C gene, the suitable locus-specific first amplification primers have the sequences:

AGCGAGGXGC CCGCCCGGCG A

SEQ ID NO.: 30,

GAGGGAAACG GCCTCTGCGG A

SEQ ID NO.: 31,

GAGGGGCCCG CCCGGCGA

SEQ ID NO.: 32,

or

GACCCGGGGA GCCGCGCA

SEQ ID NO.: 33.

These locus-specific amplification primers are complementary to the region of the non-coding strand spanning nucleotides 42 to 62 (SEQ ID No.: 30), 17-37 (SEQ ID No.: 31), 45-62 (SEQ ID No.: 32) and 71-88 (SEQ ID No.: 33) of intron 1 of the HLA-C gene sequence (SEQ ID No.: 7) as shown in Fig. 2. It will be appreciated that these



- 15 -

amplification primers could be made longer by adding additional complementary bases to either or both ends. The amplification primer might also be made somewhat shorter. The nucleotides complementary to nucleotides 34 and 37 for SEQ ID NO.: 31, 56 and 61 for SEQ ID NO.: 32, and 78 and 87 for SEQ ID NO.: 33 should be retained in the amplification primer, since these bases are distinct in the HLA-C intron from both HLA-A and HLA-B. In addition, complementary amplification primers which bind to the corresponding portions of the coding strand could be used with a compatible second amplification primer. The use of such longer or shorter amplification primers and of complementary amplification primers is within the scope of the present invention.

Suitable locus specific second amplification primers which are compatible to the coding strand include:

CGCTGATCCC ATTTTCCTCC CCTC	SEQ ID NO.: 34,
GGAGATGGGG AAGGCTCCCC ACT	SEQ ID NO.: 29,
CTCAGGAAAA CTCATSCCAT TCTCCATTCA AG	SEQ ID NO.: 35,
ACCACAGCTG CTGCAGTGGT CAAAGTG	SEQ ID NO.: 36,
GAGGAAAGGT CAGCAGCCTG ACCACA	SEQ ID NO.: 37,
or	
GA CTCAGAAA AGCTGGAATC AAACCTT	SEQ ID NO.: 38.

These locus-specific amplification primers bind to the region of the coding strand of intron 3 of the HLA-C gene (SEQ ID No.: 9) spanning nucleotides 65-88 (SEQ ID NO.: 34), 12-34 (SEQ ID No.: 29), 106-137 (SEQ ID No.: 35), 267-291 (SEQ ID NO.: 36), 283-304 (SEQ ID NO.: 37), 342-368 (SEQ ID NO.: 38), respectively, as shown in Fig. 4. As in the case of the first amplification primers, amplification primers which are made a few bases longer by virtue of adding additional complementary bases, amplification primers which are a few bases shorter, and complementary amplification primers may be used in the method of the present invention. The primers SEQ ID Nos.: 28, and 29-39 are specific for both B and C loci, therefore this primers can be used for HLA-C amplification when it is paired with an HLA-C-locus-specific 5' primer such as SEQ ID NO.: 31, SEQ ID NO.: 32, or SEQ ID NO.: 33.

- 16 -

Suitable probes for use in hybridization assays of the type of the amplified product made using these amplification primers are described in Levine et al. *Tissue Antigens* 44: 174-183 (1994) and in Table 1.

A further aspect of the present invention is determination of the allelic type of the non-classical Class I genes, i.e., HLA-E, -F, -G, -H, -J, -K and -L. In this case, the primers which we have identified as providing the most unique locus specific amplification for this purpose are located with exon 2 and exon 3 of the respective HLA gene. These locus specific amplification primers are used in the same general manner as the amplification primers discussed above for HLA-A, with specific differences being noted below.

For typing the HLA-E gene, the first amplification primer has the sequence  
CACTCCTTGA AGTATTTCCTCA CACT SEQ ID No.: 41

or

TGGAAACGGC CTCTACCGGG AGTAGAG SEQ ID No.: 42.

SEQ ID No.: 41 is complementary to the region of the non-coding strand spanning nucleotides 6-29 of exon 2 (SEQ ID No.: 39) of the HLA-E gene sequence shown in Fig. 6. SEQ ID No.: 42 is complementary to the region of the non-coding strand spanning nucleotides 19-45 of intron 1 of the HLA-E gene sequence (SEQ ID No.: 43).

It will be appreciated that these amplification primers could be made longer by adding additional complementary bases to either or both ends. The amplification primer might also be made somewhat shorter, for example spanning at least nucleotides 6-12 for SEQ ID No.: 41. Nucleotides complementary to nucleotides 24 and 29 for SEQ ID No.: 41 and 38-44 for SEQ ID NO.: 42 are also advantageously retained in a locus-specific primer since these bases are distinct in the HLA-E gene sequence from the rest of the genes. In addition, complementary amplification primers which bind to the corresponding portions of the coding strand could be used with a compatible second amplification primer. The use of such longer or shorter amplification primers and of complementary amplification primers is within the scope of the present invention.

Exemplary second amplification primers used in typing the HLA-E gene using the method of the invention have the sequence

TCTCCTTCCC CTTCTCCAGG TATT SEQ ID NO.: 44

or

- 17 -

CACAGTCCTA GCCCAAGAAG GAGATGGGAG AGTA

SEQ ID No.: 45.

SEQ ID No.: 44 primer binds to the region of the coding strand of exon 3 of the HLA-E gene (SEQ ID No.: 40) spanning nucleotides 238-261 as shown in Fig. 7. SEQ ID No.: 45 primer binds to the region of the coding strand of intron 3 of the HLA-E gene (SEQ ID No.: 46) spanning nucleotides 19-53. As in the case of the first amplification primer, amplification primers which are made a few bases longer by virtue of adding additional complementary bases, amplification primers which are a few bases shorter (retaining the 3'-end), and complementary amplification primers may be used in the method of the present invention.

10 Amplification of the HLA-E gene is performed using the same general methodology described for amplification of HLA-A, -B and -C genes. The cycle program in this case, however, is preferably

denaturation 94°C 22 seconds

annealing 62°C 50 seconds

15 extensions 72°C 30 seconds.

Suitable probes for use in hybridization assays of the type of the amplified product made using these amplification primers are listed in Table 1.

For typing the HLA-F gene, the first amplification primer has the sequence

AGGTATTTCA GCACCGCTGT GTCG

SEQ ID NO.: 47

20 or

GTGAGTGCGG GGTCCAGAGA

SEQ ID No.: 48.

SEQ ID No.: 47 amplification primer is complementary to the region of the non-coding strand spanning nucleotides 15-38 of exon 2 of the HLA-F gene sequence (SEQ ID No.: 39). SEQ ID No.: 48 amplification primer is complementary to the region of the non-coding strand spanning nucleotides 1-20 of intron 1 of the HLA-F gene sequence (SEQ ID No.: 49) shown in Fig. 2. It will be appreciated that these amplification primer could be made longer by adding additional complementary bases to either or both ends. The amplification primer might also be made somewhat shorter, for example spanning at least nucleotides 15-20 for SEQ ID No.: 47. The nucleotides complementary to nucleotides 24, 25, 30, 32 and 38 for SEQ ID No.: 47 and 15, 16, 19, and 20 for SEQ ID No.: 48 are also advantageously retained in a locus-specific amplification primer, since these bases are

25

30

- 18 -

distinct in the HLA-F sequence from the rest of the genes. In addition, complementary amplification primers which bind to the corresponding portions of the coding strand could be used with a compatible second amplification primer. The use of such longer or shorter amplification primers and of complementary amplification primers is within the scope of the present invention.

Examples of the second amplification primer used in typing the HLA-F gene using the method of the invention have the sequence

GCGTCTCCTT CCCATTCTCC AA

SEQ ID NO.: 50

or

CAACCTTGTG CGAGGCCATC CCA

SEQ ID No.: 51.

SEQ ID No.: 50 amplification primer binds to the region of the coding strand of exon 3 of the HLA-F gene (SEQ ID No.: 40) spanning nucleotides 243-264. SEQ ID No.: 51 amplification primer binds to the region of the coding strand of intron 3 of the HLA-F gene (SEQ ID No.: 52) spanning nucleotides 46-68. As in the case of the first amplification primer, amplification primers which are a made a few bases longer by virtue of adding additional complementary bases, amplification primers which are a few bases shorter (retaining the 3'-end), and complementary amplification primers may be used in the method of the present invention.

Amplification of the HLA-F gene is performed using the same methodology described for amplification of HLA-A, -B and -C genes, and the same cycle program described for amplification of the HLA-E gene.

Suitable probes for use in hybridization assays of the type of the amplified product made using these amplification primers are listed in Table 1.

For typing the HLA-G gene, the first amplification primer has, for example, the sequence

GGTTCGACAG CGACTCGGCG T

SEQ ID NO.: 53

or

CGGCGGGGGC GCAGGACTCG GCA

SEQ ID NO.: 54.

SEQ ID NO.: 53 amplification primer is complementary to the region of the non-coding strand spanning nucleotides 103-123 of exon 2 of the HLA-G gene sequence (SEQ ID No.: 39). SEQ ID NO.: 54 amplification primer is complementary to the region of the non-

- 19 -

coding strand spanning nucleotides 56-78 of intron 1 of the HLA-G gene sequence (SEQ ID No.: 55). It will be appreciated that this amplification primer could be made longer by adding additional complementary bases to either or both ends. The amplification primer might also be made somewhat shorter. The nucleotides complementary to nucleotides 119, 120 and 123 for SEQ ID NO.: 53 and 79 and 80 for SEQ ID No.: 54 are advantageously retained in a locus-specific amplification primer, since these bases are distinct in the HLA-G sequence from the rest of the genes. In addition, complementary amplification primers which bind to the corresponding portions of the coding strand could be used with a compatible second amplification primer. The use of such longer or shorter amplification primers and of complementary amplification primers is within the scope of the present invention.

Suitable oligonucleotides for use as the second amplification primer used in typing the HLA-G gene using the method of the invention have the sequence

TCTCCTTCCC GTTCTCCAGG T

SEQ ID NO.: 56

or

TCCTCCTCTC CTTGTGCTAG GCCAGGCTG

SEQ ID NO.: 57.

SEQ ID NO.: 56 amplification primer binds to the region of the coding strand of exon 3 of the HLA-G gene (SEQ ID No.: 40) spanning nucleotides 241-261. This region is the same in HLA-G, -H, -J, -K, and -L genes, and the same primer can be used as a second primer in each of the amplifications. SEQ ID NO.: 36 amplification primer binds to the region of the coding strand of exon 3 of the HLA-G gene (SEQ ID No.: 40) spanning nucleotides 46-74. Slightly longer, shorter, and complementary primers can also be used.

Amplification of the HLA-G gene is performed using the same general methodology described for amplification of HLA-A, -B and -C genes. In this case, however the amplification is performed in a glycerol buffer, rather than a DMSO buffer. Thus, each reaction mixture contains 10 to 100 ng of genomic DNA in a 100  $\mu$ l volume containing 0.2 mM dNTPs, the two amplification primers at a concentration of 0.2  $\mu$ M each, 2.5 units of Taq polymerase, 10 mM Tris-HCl (pH 8.8), 1.5 mM MgCl<sub>2</sub>, 0.001% (w/v) gelatin, 50 mM KCl and 7.5% (w/v) glycerol. The cycle program for amplification in this case is preferably

denaturation	94°C	22 seconds
annealing	60°C	50 seconds

- 20 -

extensions            72°C            30 seconds.

Suitable probes for use in hybridization assays of the type of the amplified product made using these amplification primers are listed in Table 1.

For typing the HLA-H gene, a suitable first amplification primer has the sequence

5            GAGCCCCGCT TCATCTCCGT C            SEQ ID NO.: 58.

This amplification primer is complementary to the region of the non-coding strand spanning nucleotides 54-74 of exon 2 of the HLA-G gene sequence (SEQ ID No.: 39). It will be appreciated that this amplification primer could be made longer by adding additional complementary bases to either or both ends. The amplification primer might also be made somewhat shorter. The nucleotides complementary to nucleotides 69, 71 and 74 for SEQ ID No.: 58 are advantageously retained in a locus-specific amplification primer, since these bases are distinct in the HLA-H sequence from the rest of the genes. In addition, complementary amplification primers which bind to the corresponding portions of the coding strand could be used with a compatible second amplification primer. The use of such longer or shorter amplification primers and of complementary amplification primers is within the scope of the present invention.

The second amplification primer used in typing the HLA-H gene is the same as that used for HLA-G (SEQ ID NO.: 56). Alternative second amplification primers can be made from nucleotides which include nucleotides 485 (G), 486 (A) and 490 (T) in exon 3 or nucleotides 28(G) and 33(G) in intron 3.

Amplification of the HLA-H gene is performed using the same general methodology described for amplification of HLA-A, -B and -C genes in DMSO buffer. The cycle program for amplification in this case is preferably

denaturation            94°C            22 seconds  
25            annealing            58°C            50 seconds  
extensions            72°C            30 seconds.

Suitable probes for use in hybridization assays of the type of the amplified product made using these amplification primers are listed in Table 1.

For typing the HLA-J gene, the first amplification primer has the sequence

30            AGCACCGCCG TTTCCTGGCC G            SEQ ID NO.: 59

- 21 -

This amplification primer is complementary to the region of the non-coding strand spanning nucleotides 24-44 of exon 2 of the HLA-G gene sequence (SEQ ID No.: 39). It will be appreciated that this amplification primer could be made longer by adding additional complementary bases to either or both ends. The amplification primer might also be made somewhat shorter. The nucleotides complementary to nucleotides 30, 35, 39, and 44 for SEQ ID NO. 59 are advantageously retained in a locus specific amplification primer, since these bases are distinct in the HLA-J sequence from the rest of the genes. In addition, complementary amplification primers which bind to the corresponding portions of the coding strand could be used with a compatible second amplification primer. The use of such longer or shorter amplification primers and of complementary amplification primers is within the scope of the present invention.

The second amplification primer used in typing the HLA-J gene is the same as that used for HLA-G (SEQ ID NO.: 56).

Amplification of the HLA-J gene is performed using the same methodology described for amplification of the HLA-G gene.

Suitable probes for use in hybridization assays of the type of the amplified product made using these amplification primers are listed in Table 1.

For typing the HLA-K gene, the first amplification primer has the sequence  
ACTCCATAAG GTAGTTCAGC ACCGCC SEQ ID NO.: 60

This amplification primer is complementary to the region of the non-coding strand spanning nucleotides 7-32 of exon 2 of the HLA-K gene sequence (SEQ ID No.: 39). It will be appreciated that this amplification primer could be made longer by adding additional complementary bases to either or both ends. The amplification primer might also be made somewhat shorter, for example spanning at least nucleotides 7-15. In addition, complementary amplification primers which bind to the corresponding portions of the coding strand could be used with a compatible second amplification primer. The use of such longer or shorter amplification primers and of complementary amplification primers is within the scope of the present invention.

The second amplification primer used in typing the HLA-K gene is the same as that used for HLA-G (SEQ ID NO.: 56).

Amplification of the HLA-K gene is performed using the same methodology described for amplification of the HLA-G gene.

Suitable probes for use in hybridization assays of the type of the amplified product made using these amplification primers are listed in Table 1.

5 For typing the HLA-L gene, the first amplification primer has the sequence  
GTGCGGTTCG ACAGCGACTC CGT SEQ ID NO.: 61

This amplification primer is complementary to the region of the non-coding strand spanning nucleotides 99-121 of exon 2 of the HLA-L gene sequence (SEQ ID No.: 39). It will be appreciated that this amplification primer could be made longer by adding additional  
10 complementary bases to either or both ends. The amplification primer might also be made somewhat shorter. The nucleotides complementary to nucleotides 117 and 121 for SEQ ID No.: 61 are advantageously retained in the locus-specific amplification primer, since these bases are distinct in the HLA-L sequence from the rest of the genes. In addition,  
15 complementary amplification primers which bind to the corresponding portions of the coding strand could be used with a compatible second amplification primer. The use of such longer or shorter amplification primers and of complementary amplification primers is within the scope of the present invention.

The second amplification primer used in typing the HLA-L gene is the same as that used for HLA-G (SEQ ID NO.: 56).

20 Amplification of the HLA-L gene is performed using the same methodology described for amplification of the HLA-G gene.

Suitable probes for use in hybridization assays of the type of the amplified product made using these amplification primers are listed in Table 1.

The primers used in the determination of HLA type in accordance with the invention  
25 can be made by any of the methods known in the art, and indeed companies now exist which will make a desired oligonucleotide to order. Examples of suitable synthetic approaches for primers include the phosphoramidite method.

The amplification primers which are themselves an aspect of the invention may be modified using methods known in the art to include a detectable label or a capture moiety  
30 such as biotin. For example, a fluorophore can be added to the 5'-terminus of a primer by synthesizing the oligonucleotide with a 5'-aliphatic amino group and then coupling the



- 23 -

amino group to an activated dye precursor. The 3'-terminus of an last oligonucleotide can be labeled using Terminal deoxynucleotidyl transferase to add a single extra fluorescently-labeled nucleotide from a fluorescent dideoxy(NTP) precursor. All necessary reagents for this 3'-labeling procedure are available commercially. (ABI, Boehringer, Clontech). Such labeled primers may be useful as sequencing primers for determining the sequence of the amplified portion of the gene.

Amplification primers in accordance with the invention may be advantageously packaged in kits for the typing of tissue samples. Such kits may contain, for example, at least one pair of amplification primers, including at least one locus-specific amplification primer, effective to amplify at least one HLA Class I gene. In addition the kits may include some or all of the following:

- (1) one or more reagents for the amplification of the HLA gene using the primers, e.g., a polymerase enzyme, a buffer, and individual nucleotide bases;
- (2) one or more sequencing primers suitable for sequencing exons 2 and 3 of the gene(s) amplified by the primer pair(s), together with optional sequencing reagents such as polymerase;
- (3) one or more sequence-specific oligonucleotide probes useful for determining the HLA type of the gene(s) amplified by the primer pair(s); and
- (4) reagents for sample preparation. Such kits may also include instructions for carrying out the tissue preparation and typing, containers, dot blot membranes or other solid supports for hybridization assays.

#### EXAMPLE 1

Genomic DNA was prepared from samples of each of 106 cell lines of the cell panel of the 10th International Histocompatibility Workshop using proteinase K digestion as described by Levine et al., *Tissue Antigens* 44: 174-183 (1994). The name and HLA-A, HLA-B and HLA-C types of each of these cell lines is listed in Fig. 8.

A portion of each prepared sample was amplified using one of the probe combinations described above, i.e.,

- |           |                             |
|-----------|-----------------------------|
| for HLA-A | Seq ID Nos.: 11 and 13;     |
| for HLA-B | Seq ID Nos.: 23 and 26; and |
| for HLA-C | Seq ID Nos.: 30 and 29      |

- 24 -

	for HLA-E	Seq ID Nos.: 41 and 44
	for HLA-F	Seq ID Nos.: 47 and 50
	for HLA-G	Seq ID Nos.: 53 and 56
	for HLA-H	Seq ID Nos.: 58 and 56
5	for HLA-J	Seq ID Nos.: 59 and 56
	for HLA-K	Seq ID Nos.: 60 and 56
	for HLA-L	Seq ID Nos.: 61 and 56

under the conditions described above. The amplified products were then applied to a positively charged nylon membrane (Boehringer Mannheim, Germany) using an eight channel syringe. After air-drying for one hour, DNA dotted on the membrane was denatured in 0.4 M NaOH. After neutralization, DNA was UV cross-linked to the membrane by exposing it for 5 minutes in a Stratalinker 2400 (Stratagene).

Oligonucleotide probes as shown in Table 1s were 3'-end labeled with digoxigenin-ddUTP (Boehringer Mannheim) in accordance with the manufacturers instructions. The membranes were then hybridized with digoxigenin-ddUTP labeled oligonucleotide probes (1 pmol/ml hybridization solution) of the types for one hour. The hybridization was conducted at 46°C for 15-mer probes and 54°C for 18-mer probes. The membranes were then washed in TMAC at 54°C and 58°C, respectively, for 20 minutes. Washed membranes were treated with anti-digoxigenin Fab antibody conjugated to alkaline phosphatase (Boehringer Mannheim) after treatment with blocking agent in accordance with the manufacturers protocol. The washed and treated membranes were then treated with Lumiphos 480 (Life Codes, Stamford CT) according to the manufacturers instructions and imaged using Kodak X-Omat X-Ray film for 1 to 60 minutes.

A first set of membranes was used to test the locus specificity of the amplification primers of the invention using locus-specific probes. In this set of tests, each membrane had amplifications products for each locus on it as shown in Table 2.

TABLE 2 - PROTOCOL FOR LOCUS SPECIFICITY TEST	
GENE	CELL LINES TESTED
HLA-A	1, 2, 5, 6, 7, 8, 9, 10, 13, 14, 16, 19, 22, 29, 35, 50, 53, 58, 64, 66, 71, 106, 107, NEGATIVE CONTROL
HLA-B	SAME AS HLA-A
HLA-C	SAME AS HLA-A
HLA-E	24, 25, 26, 28, 30, 41, 48, 55
HLA-F	13, 14, 16, 19, 22, 29, 35, 50
HLA-G	SAME AS HLA-F
HLA-H	63, 64, 65, 66, 67, 68, 69, 70
HLA-J	SAME AS HLA-F
HLA-K	7, 13, 16, 19, 22, 29, 35, 50
HLA-L	SAME AS HLA-F

These membranes were hybridized with probes 131R (and HLA-A and HLA-A specific probe); HBB034 (an HLA-B specific probe) HYB035 (HLA-C, G, L and B54 specific); EE2-210 (HLA-E specific); FE2-200 (HLA-F specific) GE3-183 (HLA-G specific) HE3-479 (HLA-H specific); JE3-274 (HLA-J and -K specific); and HLB032 (HLA-L specific).

Probe 131 R showed positive hybridization with all cell lines amplified with the HLA-A specific probes and all cell lines except cell line 35 and 50 amplified with the HLA-L specific probes; and no positive hybridization results with any other amplification products.

Probe HBB034 showed positive hybridization with all cell lines amplified with the HLA-B specific probes; and no positive hybridization results with any other amplification products.

Probe HYB035 showed positive hybridization with all cell lines except cell lines 35 and 107 amplified with the HLA-C specific probes and all cell lines except cell line 35 amplified with the HLA-G or K specific probes. One false positive hybridization result was noted for cell line 107 amplified with the HLA-B specific probes. This is consistent with published sequence data which shows that the cell line carries the HLA-Cw consensus sequence in the site from which HBB034 was derived.

- 26 -

Probe EE2-210 showed positive hybridization with all cell lines amplified with the HLA-E specific probes; and no positive hybridization results with any other amplification products.

5 Probe FE2-200 showed positive hybridization with all cell lines amplified with the HLA-F specific probes; and no positive hybridization results with any other amplification products.

Probe GE3-183 showed positive hybridization with all cell lines amplified with the HLA-G specific probes. False positive hybridization results were also obtained for all cell lines amplified with the HLA-L specific probes.

10 Probe HE3-479 showed positive hybridization with all cell lines amplified with the HLA-H specific probes; and no positive hybridization results with any other amplification products.

15 Probe JE3-274 showed positive hybridization with all cell lines amplified with the HLA-J and K specific probes; and no positive hybridization results with any other amplification products.

Probe HLB032 showed positive hybridization with all cell lines amplified with the HLA-L specific probes; and no positive hybridization results with any other amplification products. This probe can therefore be used to confirm a positive result obtained using GE3-183.

20

#### EXAMPLE 2

A second experiment was performed using membranes prepared in accordance with Example 1, except that the membranes were dotted with the amplification products from all 106 cell lines shown in Fig. 7. The membranes also contained a panel of amplification products from the non-classical genes, as follows:

25	<u>Gene</u>	<u>Cell Lines</u>
	HLA-E	4, 5, 6,
	HLA-F	19, 20, 21
	HLA-G	33, 34
	HLA-H	49, 50, 51
30	HLA-J	64, 65, 66
	HLA-K	79, 80, 81

- 27 -

HLA-L 94, 95, 96

5 In this experiment, HLA-A specific probes 114 EH and 142 IK were hybridized with membranes dotted with amplification products formed using the HLA-A specific primers plus the non-classical panel; and HLA-B specific probes HYE024, HXC008, HBC009 and HBB055 were hybridized with membranes dotted with amplification products formed using the HLA-B specific primers plus the non-classical panel.

10 On all of the membranes, a positive hybridization result was obtained for every cell lines which met the known specificity of the probe, as set forth in Table 2. No positive results were detected for cell lines with different allelic types. Thus, locus-specific amplification is achieved using the primer combinations of the invention.

### EXAMPLE 3

15 Three additional membranes were prepared in accordance with the protocols in Example 1. The first membrane was dotted with samples for all 106 cell lines amplified with generic (not locus-specific) HLA amplification primers having the sequence  
GGCYGGGGTC ACTCACCG SEQ ID No.: 18  
and

20 TGCAGCGTCT CCTTCCCGTT SEQ ID No.: 84  
The second was dotted with samples for all 106 cell lines amplified with the HLA-B specific amplification primers Seq ID Nos.: 3 and 4 of the invention. The third was dotted with samples for all 106 cell lines amplified with the HLA-C specific amplification primers Seq ID Nos.: 5 and 6 of the invention. These membranes were then hybridized with probe 156R which binds to several HLA-B and HLA-C allelic types.

The membrane dotted with generic amplification products revealed no specificity, with all cell lines producing a positive hybridization result. In contrast, with HLA-B amplified fragments, the probe reacted only with amplified products from cell lines 1, 13, 17, 33, 34, 42, 65, 81, 82 and 83, the cell lines which have allelic types recognized by the 156R probe. On the membrane dotted with HLA-C amplified fragments, the probe showed a positive hybridization reaction with all samples carrying Cw1, Cw4, Cw5, Cw8 and Cw14 but not

- 28 -

with those with other HLA-C allelic types. This test further demonstrates the locus specificity of the amplification procedure of the invention.

- 29 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Yang, Soo Young  
Cereb, Nezh
- (ii) TITLE OF INVENTION: Methods and Reagents for Typing HLA Class I Genes
- (iii) NUMBER OF SEQUENCES: 84
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Oppedahl & Larson
  - (B) STREET: 1992 Commerce Street Suite 309
  - (C) CITY: Yorktown
  - (D) STATE: NY
  - (E) COUNTRY: US
  - (F) ZIP: 10598
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
  - (B) COMPUTER: IBM compatible
  - (C) OPERATING SYSTEM: MS DOS
  - (D) SOFTWARE: Word Perfect
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Larson, Marina T.
  - (B) REGISTRATION NUMBER: 32,038
  - (C) REFERENCE/DOCKET NUMBER: MSK.P-001-US
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (914) 245-3252
  - (B) TELEFAX: (914) 962-4330
  - (C) TELEX:

## (2) INFORMATION FOR SEQ ID NO: 1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 130
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: Genomic DNA
- (iii) HYPOTHETICAL: no
- (iv) ANTI-SENSE: no
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:

- 30 -

(A) ORGANISM: human

(D) OTHER INFORMATION: consensus sequence of intron 1 of the HLA-A gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GTGAGTGCGG GGTCGKGAGG GAAACSGCCT CTGYGGGGAG AAGCAASGGG  
50  
CCCKCCYGGC GGGGRCGCAR GACCSGGGDA GCCGCGCKG GASGAGGGTC  
100 GCKYRGRTCT CAGCCWCTSC TCGYCCCCAG 130

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 242

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: consensus sequence of intron 2 of the HLA-A gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GTGAGTGACC CCRGCCSGGG GCGCAGGTCA SGACCYCTCA TCCCCACGG  
50 ACGGGCCRGG TSCRCCACA GTCTCCGGGT CCGAGATCCR CCCCAGGCC  
100  
GCGGGACYCC GAGACCCTTG HCCCGGGAGA GGCCCAGGCG CCTTWACCCG  
150  
GTTTCATTTT CAGTTTAGGC CAAAAATYCC CCCRGGTTGG TCGGGGCBGG  
200  
RCRGGGCTYG GGGGACYGGG CTGACCKYGG GGTCSGGGCC AG 242

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 650

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: consensus sequence of intron 3 of the HLA-A gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:



- 31 -

GTACCAGGGG CCACRGRGCG CCTMCCTGAT CGCCTRTAGR TCTCCCGGGC  
50 TGGCCTCCCA CAAGGAGGGG AGACAWTTGG GACCAACACT  
AGAATATCRC 100 CCTCCCTCTG GTCCTGAGGG AGAGGAMTCC  
TCCTGGGTTT CCAGATCCTG 150  
TACCAGAGAG TGACTCTGAG GTTCCGCCCT GCTCTSTGAC WCAATTAAGG  
200 GATAAAATCT CTGAMGGART GACGGDAAGA CGATCCCTCG  
AATACTGATG 300 ASTGGTTCCC TTTGACACAC ACMGGCAGSA  
GCCTTGGGMC CGTGACTTTT 350  
CCTCTCAGGC CTTGTTCTCT GCTTCACACT CAATGTGTGT GGGGGTCTGA 400  
GTCCAGCACT TCTGAGTCYY TCAGCCTCA CTCAGGTCAG GACCAGAAGT  
450 CGCTGTTCCC TYYTCAGGGA MTAGAATTTT CCACGGAATA  
GGAGATTATC 500  
CCAGGTGCCT GTGTCCAGGC TGGTGTCTGG GTTCTGTGCT CYCTTCCCCA  
550 TCCCRGGTGT SCTGTCCATT CTCAAGATRG SCACATGYRT  
GCTGGWGGAG 600 TGTCCCATKA CAGATRCMMA ATGCCTGMAT  
KWTCTGACTC TTCCYWCAG 650

## (2) INFORMATION FOR SEQ ID NO: 4:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 129

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: consensus sequence of intron 1 of the HLA-B gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GTGAGTGCGG GRTCGGSAGG GAAATGGCCT CTGYVGGGAG GAGMGAGGGG  
50 ACCTCAGGCG GGGGCGCAGG ACCYGRGGAG CCGCGCCGGG  
AGGAGGGTCK 100 GCGGGGTYTC AGCYCCTCCT BRCCCCCAG  
129

## (2) INFORMATION FOR SEQ ID NO: 5:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 252

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

- 32 -

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: consensus sequence of intron 2 of the HLA-B gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GTGAGTGACC CCGGCCYGGG GCGSAGGTCA CGACTCCCCA TCCCCACGK  
50 ACGBBCCGGG TCGCCCCGAG TCTCCGGGTC CGAGATCCRM  
CYCCCTGAGG 100 CYGSGGGAMC CGCCCAKACC CTCGACCGGM  
GAGAGCCSCA GCGCGGTTTA 150  
CCCGGTTTCA TTTTCAGTTG AGGCCAAAAA TCCCCGCGGG TTGGKCRGGG  
200 CGGGGCGGGG CGGGGCTCGG GGGGACKGKG CTGWCCGCGG  
GGBSKGGKCC 250  
AG 250

## (2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 575

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: consensus sequence of intron 3 of the HLA-B gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GTACCAGGGG CAGTGGGGAG CTBCCCCAT CTCCTATAGG TCGSCGGGGA  
50 TGGSTCCMA CGAGAAGARG AGGAAAATGG GATCAGCGCT  
AGAATGTCGC 100 CCTCCCTTGA ATGGAGAATG GCATGAGTTT  
TCCTGAGTTT CCTCTGAGGG 150  
CCCCCTCTT TCTCTAGGAC AATTARGGRA TGACGTCTCT GAGGAAATGG  
200 AGGGGAAGWC AGYCCCTAGR ATASTGATCA GGGGTCCYCT  
TTGACCCCTG 250 CAGCAGCCTT GGGAACCRGT ACTTTTCYTC  
TCAGRCCTTG TTCTCTGCCT 300  
CACACTCAGT GTGTTTGGGG CTCTGATTCC AGYACTTCTG AGTCACTTTA  
350 CCTCCACTCA GATCRGGAGC AGAAGTCYCT GTTCCCCGCT  
CAGAGACTCG 400 AACTTTCCAA TGAATAGGAG ATTATCCAG  
GTGCCTGCRT CCAGGCTGGT 450  
GTCTGGGTTC TGTGYCCCTT CCCCACMCCA GGTGTCCTGY CCATTCTCAG  
500 KCTGGTCACA TGGGTGGTCC TAGGGTGTSC CATGARAGAT  
GCMAAGCGCC 550 TGAWWTTTCT GACTCTTCCC ATCAG 575

## (2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 130

(B) TYPE: nucleic acid

- 33 -

(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: Genomic DNA  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: consensus sequence of intron 1 of the HLA-C gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:  
GTGAGTGCGR GGTTRGGAGG GAADCGGCCT CTGSGGAGAG GARCGAGGKG  
50 CCKKCCCGGC GAGGGCGCAG GACCCGGGGA GCCGCGCAGG  
GAGGWGGGTC 100 GGGCGGGTCT CAGCCMCTCC TCKYCCCCAG  
130

(2) INFORMATION FOR SEQ ID NO: 8:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 252  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: Genomic DNA  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: consensus sequence of intron 2 of the HLA-C gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:  
GTGAGTGACC CCRGCCCGGG GCGCAGGTCA CGACCCCCCC YCATCCCCCA  
50 CGGACGGCCC GGGTCGCCCC RAGTCTCCSS GTCTGAGATC CACCCCAAGG  
100 TGGATCTGCG GAACCCGCCC AGACCCTCGA CCGGAGAGAG  
CCCYAGTCRC 150  
CTTTACCCGG TTTCATTTTC RGTTTAGGCC AAAAATCCCC GCSGKTTGGT 200  
CGGGRCKGGG GCGGGGCTCG SGGGACKGKG YTGACCRCGG GGGCGGSGCC  
250  
AG 252

(2) INFORMATION FOR SEQ ID NO: 9:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 587  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: Genomic DNA  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no

- 34 -

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: consensus sequence of intron 3 of the HLA-C gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GTACCAGGGG CAGTGGGGAG CCTCCCCAT CTCCYRTAGA TCTCCCGGSA  
50  
TGGCCTCCCA CGAGGAGGGG AGGAAAATGG GATCAGCGCT RGAATATCGC  
100  
CCTCCCTTGA ATGGAGAATG GSATGAGTTT TCCYGAGTTT CYTCTGARGG  
150  
CCCCSTCTGC TCTCTAGGAC AATTAAGGGA TGAAGTCYYT GAGGAAATGG  
200  
AGGGGAAGAC AGTCCCTRGA ATACTGATCA GGGGTCYCCT TTGACCACTT  
250  
TGACCACTGC RGCAGCTGTG GTCAGGCTGC TGACCTTTCT CTCAGGCCTT  
300  
GTTCTCTGCC TCAYRYTCAA TGTGTYTRAA GGTTCGATTC CAGCTTTTCT 350  
GAGTYCTKCR GCCTCCACTC AGGTCAGGAC CAGAAGTCGC TGTCCTCCC  
400  
TCAGAGACTA GAACTTTCCA AWGAATAGGA GATTATCCCA GGTSCCTGTG  
450  
TCCAGGCTGG CGTCTGGGTT CTGTGCCSCC TTCCCYACCC CAGGTGTCCT 500  
GTCCRTTCTC AGGATRGTC CATGGSCRCT GYTGGAGTGT CSCAAGAGAG  
550  
AWRCAAAGTG TCTGAATTTT CTGACTCTTC CCGTCAG 587

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: intron 1 primer for locus specific amplification of exons 2 and 3 of HLA-A gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GGCCTCTGYG GGGAGAAGCA A 21

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- 35 -

(A) LENGTH: 25  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: intron 1 primer for locus specific amplification of exons 2 and 3 of HLA-A gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:  
GAAACSGCCT CTGYGGGGAG AAGCC 25

(2) INFORMATION FOR SEQ ID NO: 12:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: intron 3 primer for locus specific amplification of exons 2 and 3 of HLA-A gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:  
CGGGAGATCT AYAGGCGATC AGG 23

(2) INFORMATION FOR SEQ ID NO: 13:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: intron 3 primer for locus specific amplification of exons 2 and 3 of HLA-A gene

- 36 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:  
TGTGGTCCC AATTGTCTCC CCTC 24

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: intron 3 primer for locus specific amplification of exons 2 and 3 of HLA-A gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:  
AGGATTCCTC TCCCTCAGGA CCAG 24

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: sequencing primer for exon 2 of HLA-A, -B or -C genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:  
GGGTCKGKYR GRITYCAGC 19

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

- 37 -

(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: sequencing primer for exon 2 of HLA-A, -B or -C genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:  
CGCSCMKGGA SGWGGGTC 18

(2) INFORMATION FOR SEQ ID NO: 17:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: sequencing primer for exon 2 of HLA-A, -B or -C genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:  
TCYCACTCCA TGAGGTATTT C 21

(2) INFORMATION FOR SEQ ID NO: 18:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: sequencing primer for exon 2 of HLA-A, -B or -C genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:  
GGCYGGGGTC ACTCACCG 18

(2) INFORMATION FOR SEQ ID NO: 19:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 17  
(B) TYPE: nucleic acid

- 38 -

(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: sequencing primer for exon 2 of HLA-A, -B or -C genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:  
GTCSTGACCT SCGCCCC

17

(2) INFORMATION FOR SEQ ID NO: 20:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: sequencing primer for exon 3 of HLA-A, -B or -C genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:  
GCGGGRCGGG GCTCGGGG

19

(2) INFORMATION FOR SEQ ID NO: 21:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 17  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: sequencing primer for exon 3 of HLA-A, -B or -C genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:  
ATYCCSCRG KTTGGTC

17

(2) INFORMATION FOR SEQ ID NO: 22:



- 39 -

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: sequencing primer for exon 3 of HLA-A, -B or -C genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CCCYRYKGCC CCTGGTAC

18

## (2) INFORMATION FOR SEQ ID NO: 23:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: locus specific amplification primer for HLA-B gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GGGAGGAGCG AGGGGACCSC AG

22

## (2) INFORMATION FOR SEQ ID NO: 24:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: locus specific amplification primer for HLA-B gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

- 40 -

CGGGGGCGCA GGACCCGG

18

## (2) INFORMATION FOR SEQ ID NO: 25:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: locus specific amplification primer for HLA-B gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GGCGGGGGCG CAGGACCTGA

20

## (2) INFORMATION FOR SEQ ID NO: 26:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: locus specific amplification primer for HLA-B gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GGAGGCCATC CCCGCGACC T

21

## (2) INFORMATION FOR SEQ ID NO: 27:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

- 41 -

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: locus specific amplification primer for HLA-B gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GGAGGCCATC CCCGGCGACC TAT

23

## (2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: locus specific amplification primer for HLA-B gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CTCAGGAAAA CTCATSCCAT TCTCCATTC AAG 33

## (2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: amplification primer for HLA-B or HLA-C gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GGAGATGGGG AAGGCTCCCC ACT

23

## (2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- 42 -

(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-C gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:  
AGCGAGGXGC CCGCCCGGCG A 21

(2) INFORMATION FOR SEQ ID NO: 31:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-C gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:  
GAGGGAAACG GCCTCTGCGG A 21

(2) INFORMATION FOR SEQ ID NO: 32:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-C gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:  
GAGGGGCCCCG CCCGGCGA 18

(2) INFORMATION FOR SEQ ID NO: 33:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double

- 43 -

(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-C gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:  
GACCCGGGGA GCCGCGCA 18

(2) INFORMATION FOR SEQ ID NO: 34:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-C gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:  
CGCTGATCCC ATTTTCCTCC CCTC 24

(2) INFORMATION FOR SEQ ID NO: 35:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 32  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-C gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:  
CTCAGGAAAA CTCATSCCAT TCTCATTCA AG 32

(2) INFORMATION FOR SEQ ID NO: 36:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 27  
(B) TYPE: nucleic acid

- 44 -

(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-C gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:  
ACCACAGCTG CTGCAGTGGT CAAAGTG 27

(2) INFORMATION FOR SEQ ID NO: 37:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-C gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:  
GAGGAAAGGT CAGCAGCCTG ACCACA 26

(2) INFORMATION FOR SEQ ID NO: 38:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 27  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-C gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:  
GACTCAGAAA AGCTGGAATC AAACCTT 27

(2) INFORMATION FOR SEQ ID NO: 39:

- 45 -

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 270

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: consensus sequence of exon 2 of the nonclassical genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

GCTCCCACTC CATGAGGTAT TTCTACACCT CCGTGTCCCG GCCCGGCCGC 50  
GGGGAGCCCC GCTTCATCGC AGTGGGCTAC GTGGACGACA CGCAGTTCGT

100

GCGGTTTCGAC AGCGACGCCG CGAGTCCGAG GATGGAGCCG CGGGCGCCGT  
150

GGATAGAGCA GGAGGGGCCG GAGTATTGGG ACCGGGAGAC ACAGAACTTC  
200

AAGGCCCAACA CACAGACTGA CCGAGAGAAC CTGCGGAACC TGCGCGGCTA  
250

CTACAACCAG AGCGAGGCCG

270

## (2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 276

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: consensus sequence of exon 3 of the nonclassical HLA genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GGTCTCACAC CCTCCAGAGG ATGTATGGCT GCGACGTGGG GCCGGACGGG  
50

CGCCTCCTCC GCGGGTATAA CCAGTACGCC TACGACGGCA AGGATTACAT  
100

CGCCCTGAAC GAGGACCTGC GCTCCTGGAC CGCGGCGGAC ACGGCGGCTC  
150

- 46 -

AGATCACCCA GCGCAAGTGG GAGGCGGCCC GTGTGGCGGA GCAGCTGAGA  
200  
GCCTACCTGG AGGGCACGTG CGTGGAGTGG CTCCGCAGAT ACCTGGAGAA  
250  
CGGGAAGGAG ACGCTGCAGC GCGCGG 276

## (2) INFORMATION FOR SEQ ID NO: 41:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: locus specific amplification primer for HLA-E gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

CACTCCTTGA AGTATTCCA CACT 24

## (2) INFORMATION FOR SEQ ID NO: 42:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: locus specific amplification primer for HLA-E gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

TGGAAACGGC CTCTACCGGG AGTAGAG 27

## (2) INFORMATION FOR SEQ ID NO: 43:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 130

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double



- 47 -

(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: consensus sequence of intron 1 of the HLA-E gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:  
GTGAGTGCGG GGTCGGGATG GAAACGGCCT CTACCGGGAG TAGAGAGGGG  
50  
CCGGCCCCGGC GGGGGCGAAG GACTCGGGGA GCCGCGCCGG GAGGAGGGTC  
100  
GGGCCGATCT CAGCCCCTCC TCGCCCCCAG 130

(2) INFORMATION FOR SEQ ID NO: 44:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-E gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:  
TCTCCTTCCC CTTCTCCAGG TATT 24

(2) INFORMATION FOR SEQ ID NO: 45:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 34  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-E gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

- 48 -

CACAGTCCTA GCCCAAGAAG GAGATGGGAG AGTA

34

## (2) INFORMATION FOR SEQ ID NO: 46:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 621

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: consensus sequence of intron 3 of the HLA-E gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

GTAAGAGGGT CCACAGGGCT ACTCTCCCAT CTCCTTCTTG GGCTAGGACT  
50

GTGCCCACAG CTGACAGACC TCAAACAGTA GAAGAAACAG GGATGGAGGC

100 CAGAATACCA CTCCTCCCTT GGATCAGGAG AGGGAGCTGT

CACCTGAGGT 150 ACAGGAGATC CTATACCACA GAGTGACTCT

CTTAAAGGGC CAGACCTCTC 200 TCAGGGGCAA TTAAGGAATC

TAGTCTCGCT GGAGATTCCA TCCTTCAGAT 250 GAACTGATGA

GCAGTTCTCT TTGACTCCCA GTATTAGGAA TCACGGGGGA 300

GTTTCTCTCG TGCCTGATTC TCAGCCCCAC ACCAAGAGTT TTTGGAGGTC 350

TGACTCCAGC TTTTCTCAGT CACTCAGCAT CCACACAGGC CAGGACCAGA

400 AATCCCTTTT CACCTTCTAC CCTGGGCTAG CTCATCCCGA TTCTAGAACT

450 TTCCAAGGAA TAAGAGGCTA TCCCAGATCC CTAAGTCCAG

GCTGGTGTC 500 AGGTTTTGTC CTCTTCTCCT ACTATAATTG TCCTCTTCCT

TCTCAGGATG 550 GTCACATGGG TGCTGCTGGA GTGTCCCATG

AGAGATACAA AGTGCCTGAA 600 TTTTCTGACT CTCCCCCTCA G

621

## (2) INFORMATION FOR SEQ ID NO: 47:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

- 49 -

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: locus specific amplification primer for HLA-F gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

AGGTATTTC A GCACCGCTGT GTCG

24

## (2) INFORMATION FOR SEQ ID NO: 48:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: locus specific amplification primer for HLA-F gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

GTGAGTGCGG GGTCCAGAGA

20

## (2) INFORMATION FOR SEQ ID NO: 49:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 130

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: consensus sequence of intron 1 of the HLA-F gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

GTGAGTGCGG GGTCCAGAGA GAAACGGCCT CTGTGGGGAG GAGTGAGGGG

50

CCCGCCCGGT GGGGGCGCAG GACTCAGGGA GCCGCGCCCG GAGGAGGGTC

100

TGGCGGGTCT CAGCCCCTCC TCGCCCCCAG

130

## (2) INFORMATION FOR SEQ ID NO: 50:

## (i) SEQUENCE CHARACTERISTICS:

- 50 -

(A) LENGTH: 22  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-F gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:  
GCGTCTCCTT CCCATTCTCC AA 22

(2) INFORMATION FOR SEQ ID NO: 51:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-F gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:  
CAACCTTGTG CGAGGCCATC CCA 23

(2) INFORMATION FOR SEQ ID NO: 52:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH:  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: consensus sequence of intron 3 of the HLA-F gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:  
GTACCAGGGG CCATGGGCGC CTTCCCTATC TCCTGTAGAT CTCTTGGGAT 50

- 51 -

GGCCTCGCAC AAGGTTGGGA GGAAAGTGGG CCCAATGCTA GGATATCGCC  
100 CTCCCTCTAG TCCTGAGTAG GAAGAATCTT CCTGGCTTTT CGAGATCCGG  
150 TACCAGAGAG TGATTGTGAG AGTCCGCCCT GCTCTCTTGG  
ACAATTAAGG 200 GATGAAATGG AGGAGGACAG TCCCTGGTCC  
CCTTTGAGCC TCCAACAGCT 250 GCCGTGACTT TTCTCTCAGG TTTTGTCTCT  
GCCTCACACT CAATGTGTTT 300  
GGGGCTCTGA TTCCAGTCCC TCGCCCTCCA CTTAGTCAGG CCAGAAGTCC  
350  
CTGCTCCCGC TCAGAGACTC GAACTTTCCA AGGAATAGGA GATTTTCCCA  
400  
GGTGTCTGTG TCCAGCCTGG TGTCTGGGTT CTGTGCTCCC TTCCCCACCC 450  
CAGGTGTCCT GTCCAGTCTC AGGTTGGTCA CATGGGTGCT GCTGGGGTTT  
500  
CCCATGAGGA GTGCAAAGTG CCTGAATTTT CTGACTCTTC TCAG 544

## (2) INFORMATION FOR SEQ ID NO: 53:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: locus specific amplification primer for HLA-G gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

GGTTCGACAG CGACTCGGCG T

21

## (2) INFORMATION FOR SEQ ID NO: 54:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: locus specific amplification primer for HLA-G gene

- 52 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:  
CGGCGGGGGC GCAGGACTCG GCA 23

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 129

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: consensus sequence of intron 1 of the HLA-G gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

GTGAGTGCGG GGTGAGGAGG GAAACGGCCC CTGCGCGGAG GAGGGAGGGG  
50  
CCCCCCCCGGC GGGGGCGCAG GACTCGGCAG CCGCGCCGGG AGGAGGGTCG  
100  
GGCGGGTCTC AACCCCTCCT CGCCCCCAG 129

(2) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: locus specific amplification primer for HLA-G gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

TCTCCTTCCC GTTCTCCAGG T 21

(2) INFORMATION FOR SEQ ID NO: 57:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

- 53 -

(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-G gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:  
TCCTCCTCTC CTTGTGCTAG GCCAGGCTG 27

(2) INFORMATION FOR SEQ ID NO: 58:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-H gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:  
GAGCCCCGCT TCATCTCCGT C 21

(2) INFORMATION FOR SEQ ID NO: 59:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-J gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:  
AGCACCGCCG TTCCTGGCC G 21

(2) INFORMATION FOR SEQ ID NO: 60:  
(i) SEQUENCE CHARACTERISTICS:

- 54 -

(A) LENGTH: 26  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-K gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:  
ACTCCATAAG GTAGTTCAGC ACCGCC 26

(2) INFORMATION FOR SEQ ID NO: 61:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: locus specific amplification primer for HLA-L gene  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:  
GTGCGGTTTCG ACAGCGACTC CGT 23

(2) INFORMATION FOR SEQ ID NO: 62:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: hybridization probe 131R for typing of HLA Class I genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:



- 55 -

CGCTCTTGGA CCGCG

15

## (2) INFORMATION FOR SEQ ID NO: 63:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: hybridization probe HBB034 for typing of HLA Class I genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

GTTCGTGAGG TTCGACAGC 19

## (2) INFORMATION FOR SEQ ID NO: 64:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: hybridization probe HYB035 for typing of HLA Class I genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

CGCCGTGGGT GGAGCAGGA 19

## (2) INFORMATION FOR SEQ ID NO: 65:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- 56 -

(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: hybridization probe EE2-210 for typing of HLA Class I  
genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:  
GCACAGACAC GGAACACC 18

(2) INFORMATION FOR SEQ ID NO: 66:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: hybridization probe FE2-200 for typing of HLA Class I  
genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:  
GTCTGTGCGT TGGCCTTG 18

(2) INFORMATION FOR SEQ ID NO: 67:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: hybridization probe GE2-183 for typing of HLA Class I  
genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:  
GAGGAGACAC GGAACACC 18

- 57 -

## (2) INFORMATION FOR SEQ ID NO: 68:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: hybridization probe HE3-479 for typing of HLA Class I

genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

TCCACGAACT CGCCCTCC

18

## (2) INFORMATION FOR SEQ ID NO: 69:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: hybridization probe JE3-274 for typing of HLA Class I

genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

TTCCCTGGAG GATGTGAT

18

## (2) INFORMATION FOR SEQ ID NO: 70:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

- 58 -

(A) ORGANISM: human

(D) OTHER INFORMATION: hybridization probe HLB-032 for typing of HLA Class I genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:  
CAGCGACTCC GTGAGTCCG 19

(2) INFORMATION FOR SEQ ID NO: 71:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: hybridization probe 142IK for typing of HLA Class I genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:  
CAGATCACCA AGCGC 15

(2) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: hybridization probe 114EH for typing of HLA Class I genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:  
TATGAACAGC ACGCC 15

(2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

- 59 -

(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: hybridization probe HXC008 for typing of HLA Class I  
genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:  
CTGCGGATCG CGCTCCGCT 19

(2) INFORMATION FOR SEQ ID NO: 74:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: hybridization probe HBB055 for typing of HLA Class I  
genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:  
CCGCGAGTCC GAGGATGGC 19

(2) INFORMATION FOR SEQ ID NO: 75:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: hybridization probe HBC009 for typing of HLA Class I  
genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:

- 60 -

CTGCGGACCC TGCTCCGCT

19

## (2) INFORMATION FOR SEQ ID NO: 76:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: hybridization probe HYE024 for typing of HLA Class I

genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:

GGACCTGCGC TCCTGGACC

19

## (2) INFORMATION FOR SEQ ID NO: 77:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: hybridization probe HBD080 for typing of HLA Class I

genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77:

CGGGTACCAC CAGGACGCC

19

## (2) INFORMATION FOR SEQ ID NO: 78:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

- 61 -

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: hybridization probe HBD083 for typing of HLA Class I genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

CGGGTATGAC CAGGACGCC

(2) INFORMATION FOR SEQ ID NO: 79:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: hybridization probe HBD086 for typing of HLA Class I genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

CGGGTATAAC CAGTTAGCC

19

(2) INFORMATION FOR SEQ ID NO: 80:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: yes

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: hybridization probe HBF094 for typing of HLA Class I genes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

GACAAGCTGG AGCGCGCTG

19

(2) INFORMATION FOR SEQ ID NO: 81:

(i) SEQUENCE CHARACTERISTICS:

- 62 -

(A) LENGTH: 19  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: hybridization probe HBC065 for typing of HLA Class I genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:  
GAAGTACAAG CGCCAGGCA 19

(2) INFORMATION FOR SEQ ID NO: 82:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: hybridization probe HBC066 for typing of HLA Class I genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:  
GAACATGAAG GCCTCCGCG 19

(2) INFORMATION FOR SEQ ID NO: 83:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: other nucleic acid  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: yes  
(v) FRAGMENT TYPE: internal  
(vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(D) OTHER INFORMATION: hybridization probe 156R for typing of HLA Class I genes  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83:  
GCGGAGCAGC GGAGAGCC 18



- 63 -

## (2) INFORMATION FOR SEQ ID NO: 84:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(D) OTHER INFORMATION: generic amplification primer for HLA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

TGCAGCGTCT CCTTCCCGTT

20

## CLAIMS

1           1.     A method for testing a tissue sample to determine the allelic type of an  
2     HLA Class I gene in the sample, said HLA Class I gene being selected from among HLA-  
3     A, HLA-B and HLA-C genes comprising the steps of  
4                 (a) treating the tissue sample to obtain nucleic acid polymers suitable for  
5     amplification;  
6                 (b) combining the nucleic acid polymers with a first primer which  
7     hybridizes with a portion of intron 1 or intron 3 of the HLA Class I gene, and a second  
8     primer which hybridizes with a different portion of the HLA Class I gene under conditions  
9     suitable for amplification to obtain an amplified product; and  
10                (c) evaluating the amplified product to determine the allelic type of the  
11     HLA-Class I gene.

1           2.     The method of claim 1, wherein at least one of the first primer and the  
2     second primer specifically hybridizes with the selected HLA Class I gene to provide locus-  
3     specific amplification.

1           3.     The method of claim 1 or 2, wherein the first primer hybridizes with  
2     intron 1 and the second primer hybridizes with intron 3 of the selected HLA Class I gene.

1           4.     The method of any of claims 1 to 3, wherein the HLA Class I gene is  
2     an HLA-A gene, and the first primer is an oligonucleotide which is complementary to or  
3     has the same sequence as a portion of SEQ ID No.: 1.

1           5.     The method of any of claims 1 to 3, wherein the HLA Class I gene is an  
2     HLA-A gene, and the first primer is an oligonucleotide which is complementary to or has  
3     the same sequence as a portion of SEQ ID No.: 3.

1           6.     The method of any of claims 1 to 3, wherein the HLA Class I gene is an  
2     HLA-B gene, and the first primer is an oligonucleotide which is complementary to or has  
3     the same sequence as a portion of SEQ ID No.: 4.

1           7.     The method of any of claims 1 to 3, wherein the HLA Class I gene is an  
2     HLA-B gene, and the first primer is an oligonucleotide which is complementary to or has  
3     the same sequence as a portion of SEQ ID No.: 6.

1           8.     The method of any of claims 1 to 3, wherein the HLA Class I gene is an  
2     HLA-C gene, and the first primer is an oligonucleotide which is complementary to or has  
3     the same sequence as a portion of SEQ ID No.: 7.

1           9.     The method of any of claims 1 to 3, wherein the HLA Class I gene is an  
2     HLA-C gene, and the first primer is an oligonucleotide which is complementary to or has  
3     the same sequence as a portion of SEQ ID No.: 9.

1           10.    The method of any of claims 1 to 9, wherein the amplified product is  
2     evaluated using sequence specific oligonucleotide probes which hybridize selectively to  
3     known alleles of the HLA gene.

1           11.    The method of any of claims 1 to 9, wherein the amplified product is  
2     evaluated by direct sequencing.

1           12.    The method of claim 11, wherein the amplified product is sequenced  
2     using a sequencing primer which hybridizes to all of the classical HLA Class I genes.

1           13.    The method of any of claims 1 to 3, wherein the first amplification  
2     primer is any of the primers identified by SEQ ID Nos.: 10-14 and 23-38.

1           14.    The method of any of claims 1 to 13, further comprising the step of  
2     testing a portion of the nucleic acid polymers from the sample to determine the type of at  
3     least one non-classical HLA Class I genes.

- 66 -

1           15.    The method of claim 14, wherein the step of testing the portion of the  
2   nucleic acid polymers includes the steps of  
3           combining the portion of the nucleic acid polymers with a non-classical primer  
4   which specifically hybridizes with a portion of the non-classical HLA Class I gene, and a  
5   primer which hybridizes with a different portion of the non-classical HLA Class I gene  
6   under conditions suitable for amplification to obtain an amplified non-classical product; and  
7           evaluating the amplified non-classical product to determine the allelic type of  
8   the non-classical HLA-Class I gene.

1           16.    The method of claim 15, wherein the non-classical primer is any of the  
2   primers identified by SEQ ID Nos.: 41, 42, 45, 47, 48, 50, 51, 53, 54, and 56 to 61.

1           17.    An oligonucleotide having a length of from 10 to 45 bases which  
2   hybridizes with or has the same sequence as a continuous portion of intron 1, intron 2 or  
3   intron 3 of a classical HLA Class I gene.

1           18.    The oligonucleotide of claim 17, wherein the oligonucleotide is a locus-  
2   specific probe which specifically hybridizes with or has the same sequence as a portion of  
3   intron 1 of one and only one HLA Class I gene.

1           19.    The oligonucleotide of claim 17 or 18, wherein the oligonucleotide  
2   specifically hybridizes with or has the same sequence as a portion SEQ ID No.: 1.

1           20.    The oligonucleotide of claim 17 or 18, wherein the oligonucleotide  
2   specifically hybridizes with or has the same sequence as a portion SEQ ID No.: 4.

1           21.    The oligonucleotide of claim 17 or 18, wherein the oligonucleotide  
2   specifically hybridizes with or has the same sequence as a portion SEQ ID No.: 7.

- 67 -

1           22.    The oligonucleotide of claim 17, wherein the oligonucleotide is a locus-  
2   specific probe which specifically hybridizes with or has the same sequence as a portion of  
3   intron 3 of one and only one HLA Class I gene.

1           23.    The oligonucleotide of claim 17 or 22, wherein the oligonucleotide  
2   specifically hybridizes with or has the same sequence as a portion SEQ ID No.: 3.

1           24.    The oligonucleotide of claim 17 or 22, wherein the oligonucleotide  
2   specifically hybridizes with or has the same sequence as a portion SEQ ID No.: 6.

1           25.    The oligonucleotide of claim 17 or 22, wherein the oligonucleotide  
2   specifically hybridizes with or has the same sequence as a portion SEQ ID No.: 9.

1           26.    The oligonucleotide of claim 17, wherein the oligonucleotide  
2   specifically hybridizes with or has the same sequence as a portion SEQ ID No.: 2.

1           27.    The oligonucleotide of claim 17 or 26, wherein the oligonucleotide  
2   specifically hybridizes with or has the same sequence as a portion SEQ ID No.: 5.

1           28.    The oligonucleotide of claim 17 or 26, wherein the oligonucleotide  
2   specifically hybridizes with or has the same sequence as a portion SEQ ID No.: 8.

1           29.    The oligonucleotide of claim 17, wherein the oligonucleotide has the  
2   sequence given by any of SEQ ID Nos.: 10-14, 23-38, 41, 42, 45, 47, 48, 50, 51, 53, 54,  
3   and 56 to 61.

1           30.    A method for preparing an amplification primer pair for locus-specific  
2   amplification of exons 2 and 3 of a selected classical HLA Class I gene comprising the steps  
3   of:

- 4 (a) evaluating the aligned sequences of intron 1 of the classical HLA Class  
5 I gene to select an intron 1 sequence of from 10 to 40 bases which differs in the selected  
6 gene from unselected classical HLA Class I genes;
- 7 (b) scanning the known sequences of the selected and unselected classical  
8 HLA Class I genes to determine if the selected intron 1 sequence is repeated elsewhere  
9 within the genes and selecting a new intron 1 sequence if repetition is found;
- 10 (c) evaluating the aligned sequences of intron 3 of the classical HLA Class  
11 I gene to select an intron 3 sequence of from 10 to 40 bases which differs in the selected  
12 gene from unselected classical HLA Class I genes;
- 13 (d) scanning the known sequences of the selected and unselected classical  
14 HLA Class I genes to determine if the selected intron 3 sequence is repeated elsewhere  
15 within these genes and selecting a new intron 3 sequence if repetition is found; and
- 16 (e) synthesizing a pair of primers having the sequences of the selected  
17 intron 1 and intron 3 sequences.

1 31. The method of claim 30, further comprising the step of performing a  
2 test amplification using the synthesized primers and testing the amplification products with  
3 sequence specific probes to confirm locus specificity.

1 32. A kit for testing a tissue sample to determine the allelic type of an HLA  
2 Class I gene in the sample comprising, in packaged combination, at least one pair of  
3 amplification primers, said pair of amplification primers including at least a first primer  
4 which hybridizes with a portion of intron 1 or intron 3 of the HLA Class I gene.

1 33. The kit of claim 32, wherein the first primer is a locus-specific primer  
2 which specifically hybridizes with one and only one of the HLA Class I genes.

1 34. The kit of claim 32 or 33, wherein the HLA Class I gene is an HLA-A  
2 gene, and the first primer specifically hybridizes with or is the same as a continuous portion  
3 of SEQ ID NO.: 1, 2 or 3.

- 69 -

1           35.    The kit of claim 32 or 33, wherein the HLA Class I gene is an HLA-B  
2   gene, and the first primer specifically hybridizes with or is the same as a continuous portion  
3   of SEQ ID NO.: 4, 5 or 6.

1           36.    The kit of claim 32 or 33, wherein the HLA Class I gene is an HLA-C  
2   gene, and the first primer specifically hybridizes with or is the same as a continuous portion  
3   of SEQ ID NO.: 7, 8 or 9.

1           37.    The kit of any of claims 32 to 36, further comprising at least one  
2   separate container containing a sequence-specific oligonucleotide probe which hybridizes  
3   selectively to a known allele of the HLA gene.

1           38.    A method for testing a tissue sample to determine the allelic type of an  
2   HLA Class I gene in the sample, said HLA Class I gene being selected from among the  
3   non-classical HLA genes comprising the steps of

4               (a) treating the tissue sample to obtain nucleic acid polymers suitable for  
5   amplification;

6               (b)    combining the nucleic acid polymers with a locus-specific first primer  
7   which specifically hybridizes with a portion of the non-classical HLA Class I gene, and a  
8   second primer which hybridizes with a different portion of the non-classical HLA Class I  
9   gene under conditions suitable for amplification to obtain an amplified non-classical  
10   product; and

11              (c)    evaluating the amplified non-classical product to determine the allelic  
12   type of the non-classical HLA Class I gene.

1           39.    The method of claim 38, wherein the locus-specific first primer is any of  
2   the primers identified by SEQ ID Nos.: 41, 42, 45, 47, 48, 50, 51, 53, 54, and 57 to 61.

1           40.    The method of claim 38 or 39, wherein the second primer has the  
2   sequence given by SEQ ID No.: 56.

1/15

## EXON-INTRON ORGANIZATION OF HLA CLASS I GENES




Fig. 1



2/15

HLAA

GTGAGTGGGGT CGRAGGGAACSGCTCTGYGGGAGAGCAAGGGCCCKCCYGGCGGGRCGCAAGACCSGGGDAAGCCCGCCGCGGAGGGTCCGKYRGTCTCAGCCWCTSTCTGGYCCCAAG

10, 11

HLAB

GTGAGTGGGGT CGSAGGGAAATGGCTCTGYVGGAGGAGAGGGGACCGCAGGCGGGGGCGCAGGACCCYRGGAGCCCGCCGGGAGGGGTCKGGCGGGT YTCAGCYCTCTCTBRCCCCAAG

23

24

25

HLAC

GTGAGTGGGGTTRGGAGGGNADCGGCTCTGSGGAGAGGARGAGGKGCCCKCCCGGAGGGCGCAGGACCCGGGAGCCCGCAGGGAGGGGTGGGGCGGGTCTCAGGCCCTCTCKYCCCCAAG

31

30/32

33

Fig. 2

**HLA-A**

CTGAGTGAACCCCRGCCGSGGGGCGQAGGTGASGACCTCTCATTCCTCCACGACGGGCTGGTSCRCCACAGTCTTCGGGTCCGAGATCCRCCCTGAGCCGACCCCTTGHCCTCCGGAGAGG

CCGAGGCGCCTTACCCGGTTTCATTTTCAGTTTAGGCCAAAATYCCCCCRGGTGTCTGGGCGCGGRCRGGGCTYGGGGGACYGGGCTGACCKYGGGGTCTSGGGCCAG

**HLA-B**

GTGAGTGACCCCGGCCYGGGGCGSAGGTACGACTCCCATCCCCACGACGGBCGGGTGCCCCGAGTCTCCGGT:CGAGATCCRMCYCCCTGAGCCYGGGGGMCGCCCAKACCCCTCGACCGGGA

GAGCCSCAGCCGCGTTTACCGGTTTCATTTCAGTTGAGGCCCAAAATCCCGCGGGTTGGTCRGGCCGGGCGGGGCGGGGCTCGCGGGGACACGKCTGTCGCCGGGGBSKGGKCCAG

HLA-C

GTGAGTGACCCCRGGCCGGGGCCGACAGGTACAGGACCCGTCATCCCGGACGGGACGGGTCGGGTCTGAGATCAGCCCAAGGTGGATCTGGGGACCCGGCCGAGA

CCCTCGACCGGAGAGAGCCCVAGTCRCCTTTACCCGGTTTCATTTTCRCGTTTAGGCCAATAATCCCGCGGTCGGGRCACGKGVTGACACCGGCGGCGAG

**FIG. 4**

# HI.A-A

## HLA-B

## HLA-C

HLA-C

GTACAGGGGCA GTGGGAGCGCTTCCGCACTCCCTCTTTAGATCTCCCGGAGTGGCTCCACGAGGAGGGGAGGAAATGGGATCAGCGCTCGATATCGCCCTCCCTTGATGGAGAAATGGSATGAGTT  
> \_\_\_\_\_ 29 \_\_\_\_\_ < \_\_\_\_\_ 34 \_\_\_\_\_ > \_\_\_\_\_ 35 \_\_\_\_\_  
TTCTCGAGTTCTCTCTGAGGCCCCCTCTGCTCTCTAGGACAATTAGGGATGAAGTCTTTGAGGAAATGGAGGGGAGACAGTCCCTCGATACTGATCAGGGGCTCCCTTTGACCACCTTTGACCACCT  
> \_\_\_\_\_ < \_\_\_\_\_ > \_\_\_\_\_ < \_\_\_\_\_ > \_\_\_\_\_ 36 \_\_\_\_\_  
( ) \_\_\_\_\_ < \_\_\_\_\_ > \_\_\_\_\_ < \_\_\_\_\_ > \_\_\_\_\_ 38 \_\_\_\_\_  
GCGRCAGAGCTGTGGTCAGGCTGCTGACCTTCTCTCAGGCGCTTGTTCTCTGCTCAATCTGTCTTTAAGTTTGAATCCAGCTTTCTGAGTCTCTACGCTCAGGTCAGGACCAAGAGT  
> \_\_\_\_\_ 37 \_\_\_\_\_ < \_\_\_\_\_ > \_\_\_\_\_ < \_\_\_\_\_ > \_\_\_\_\_  
CGCTGTTCTCCTCCCTCAGAGAGCTAGACTTCCAAAGAAATAGGAGATATCCAGGTSCTGTGTCTCAGGCTGGGCTCTGGGCTTCTGTGCGGCTTCCGACCCAGGAGTGTCTCTCTCAGGATTA  
> \_\_\_\_\_ < \_\_\_\_\_ > \_\_\_\_\_ < \_\_\_\_\_ > \_\_\_\_\_  
GTCACATGGGSCRTGTGTGGAGTGTCSAGAGAGACATACAAAGTGTCTGCAATTTTCTGACTCTTCCCGCTCAG  
> \_\_\_\_\_ < \_\_\_\_\_ > \_\_\_\_\_ < \_\_\_\_\_ > \_\_\_\_\_

5/15

Fig. 5A  
HLA INTRON 1 Sequence

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000	1001	1002	1003	1004	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017	1018	1019	1020	1021	1022	1023	1024	1025	1026	1027	1028	1029	1030	1031	1032	1033	1034	1035	1036	1037	1038	1039	1040	1041	1042	1043	1044	1045	1046	1047	1048	1049	1050	1051	1052	1053	1054	1055	1056	1057	1058	1059	1060	1061	1062	1063	1064	1065	1066	1067	1068	1069	1070	1071	1072	1073	1074	1075	1076	1077	1078	1079	1080	1081	1082	1083	1084	1085	1086	1087	1088	1089	1090	1091	1092	1093	1094	1095	1096	1097	1098	1099	1100	1101	1102	1103	1104	1105	1106	1107	1108	1109	1110	1111	1112	1113	1114	1115	1116	1117	1118	1119	1120	1121	1122	1123	1124	1125	1126	1127	1128	1129	1130	1131	1132	1133	1134	1135	1136	1137	1138	1139	1140	1141	1142	1143	1144	1145	1146	1147	1148	1149	1150	1151	1152	1153	1154	1155	1156	1157	1158	1159	1160	1161	1162	1163	1164	1165	1166	1167	1168	1169	1170	1171	1172	1173	1174	1175	1176	1177	1178	1179	1180	1181	1182	1183	1184	1185	1186	1187	1188	1189	1190	1191	1192	1193	1194	1195	1196	1197	1198	1199	1200	1201	1202	1203	1204	1205	1206	1207	1208	1209	1210	1211	1212	1213	1214	1215	1216	1217	1218	1219	1220	1221	1222	1223	1224	1225	1226	1227	1228	1229	1230	1231	1232	1233	1234	1235	1236	1237	1238	1239	1240	1241	1242	1243	1244	1245	1246	1247	1248	1249	1250	1251	1252	1253	1254	1255	1256	1257	1258	1259	1260	1261	1262	1263	1264	1265	1266	1267	1268	1269	1270	1271	1272	1273	1274	1275	1276	1277	1278	1279	1280	1281	1282	1283	1284	1285	1286	1287	1288	1289	1290	1291	1292	1293	1294	1295	1296	1297	1298	1299	1300	1301	1302	1303	1304	1305	1306	1307	1308	1309	1310	1311	1312	1313	1314	1315	1316	1317	1318	1319	1320	1321	1322	1323	1324	1325	1326	1327	1328	1329	1330	1331	1332	1333	1334	1335	1336	1337	1338	1339	1340	1341	1342	1343	1344	1345	1346	1347	1348	1349	1350	1351	1352	1353	1354	1355	1356	1357	1358	1359	1360	1361	1362	1363	1364	1365	1366	1367	1368	1369	1370	1371	1372	1373	1374	1375	1376	1377	1378	1379	1380	1381	1382	1383	1384	1385	1386	1387	1388	1389	1390	1391	1392	1393	1394	1395	1396	1397	1398	1399	1400	1401	1402	1403	1404	1405	1406	1407	1408	1409	1410	1411	1412	1413	1414	1415	1416	1417	1418	1419	1420	1421	1422	1423	1424	1425	1426	1427	1428	1429	1430	1431	1432	1433	1434	1435	1436	1437	1438	1439	1440	1441	1442	1443	1444	1445	1446	1447	1448	1449	1450	1451	1452	1453	1454	1455	1456	1457	1458	1459	1460	1461	1462	1463	1464	1465	1466	1467	1468	1469	1470	1471	1472	1473	1474	14
---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	----

6/15

Fig. 5B  
HLA Intron 2 (Part I)

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000	1001	1002	1003	1004	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017	1018	1019	1020	1021	1022	1023	1024	1025	1026	1027	1028	1029	1030	1031	1032	1033	1034	1035	1036	1037	1038	1039	1040	1041	1042	1043	1044	1045	1046	1047	1048	1049	1050	1051	1052	1053	1054	1055	1056	1057	1058	1059	1060	1061	1062	1063	1064	1065	1066	1067	1068	1069	1070	1071	1072	1073	1074	1075	1076	1077	1078	1079	1080	1081	1082	1083	1084	1085	1086	1087	1088	1089	1090	1091	1092	1093	1094	1095	1096	1097	1098	1099	1100	1101	1102	1103	1104	1105	1106	1107	1108	1109	1110	1111	1112	1113	1114	1115	1116	1117	1118	1119	1120	1121	1122	1123	1124	1125	1126	1127	1128	1129	1130	1131	1132	1133	1134	1135	1136	1137	1138	1139	1140	1141	1142	1143	1144	1145	1146	1147	1148	1149	1150	1151	1152	1153	1154	1155	1156	1157	1158	1159	1160	1161	1162	1163	1164	1165	1166	1167	1168	1169	1170	1171	1172	1173	1174	1175	1176	1177	1178	1179	1180	1181	1182	1183	1184	1185	1186	1187	1188	1189	1190	1191	1192	1193	1194	1195	1196	1197	1198	1199	1200	1201	1202	1203	1204	1205	1206	1207	1208	1209	1210	1211	1212	1213	1214	1215	1216	1217	1218	1219	1220	1221	1222	1223	1224	1225	1226	1227	1228	1229	1230	1231	1232	1233	1234	1235	1236	1237	1238	1239	1240	1241	1242	1243	1244	1245	1246	1247	1248	1249	1250	1251	1252	1253	1254	1255	1256	1257	1258	1259	1260	1261	1262	1263	1264	1265	1266	1267	1268	1269	1270	1271	1272	1273	1274	1275	1276	1277	1278	1279	1280	1281	1282	1283	1284	1285	1286	1287	1288	1289	1290	1291	1292	1293	1294	1295	1296	1297	1298	1299	1300	1301	1302	1303	1304	1305	1306	1307	1308	1309	1310	1311	1312	1313	1314	1315	1316	1317	1318	1319	1320	1321	1322	1323	1324	1325	1326	1327	1328	1329	1330	1331	1332	1333	1334	1335	1336	1337	1338	1339	1340	1341	1342	1343	1344	1345	1346	1347	1348	1349	1350	1351	1352	1353	1354	1355	1356	1357	1358	1359	1360	1361	1362	1363	1364	1365	1366	1367	1368	1369	1370	1371	1372	1373	1374	1375	1376	1377	1378	1379	1380	1381	1382	1383	1384	1385	1386	1387	1388	1389	1390	1391	1392	1393	1394	1395	1396	1397	1398	1399	1400	1401	1402	1403	1404	1405	1406	1407	1408	1409	1410	1411	1412	1413	1414	1415	1416	1417	1418	1419	1420	1421	1422	1423	1424	1425	1426	1427	1428	1429	1430	1431	1432	1433	1434	1435	1436	1437	1438	1439	1440	1441	1442	1443	1444	1445	1446	1447	1448	1449	1450	1451	1452	1453	1454	1455	1456	1457	1458	1459	1460	1461	1462	1463	1464	1465	1466	1467	1468	1469	1470	1471	1472	1473	1474	1475	1476	1477
--	---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------

**Fig. 5C**  
**HLA Intron 2 (Part II)**

[illegible]

**Fig. 5D**  
**HLA Intron 3 (Part 1)**

[illegible]

9/15

Fig. 5E  
HLA Intron 3 (Part II)

	302	321	340	359	378	397	416	435	454	473	492	511	530	549	568	587	606	625	644	663	682	701	720	739	758	777	796	815	834	853	872	891	910	929	948	967	986	1005	1024	1043	1062	1081	1100	1119	1138	1157	1176	1195	1214	1233	1252	1271	1290	1309	1328	1347	1366	1385	1404	1423	1442	1461	1480	1499	1518	1537	1556	1575	1594	1613	1632	1651	1670	1689	1708	1727	1746	1765	1784	1803	1822	1841	1860	1879	1898	1917	1936	1955	1974	1993	2012	2031	2050	2069	2088	2107	2126	2145	2164	2183	2202	2221	2240	2259	2278	2297	2316	2335	2354	2373	2392	2411	2430	2449	2468	2487	2506	2525	2544	2563	2582	2601	2620	2639	2658	2677	2696	2715	2734	2753	2772	2791	2810	2829	2848	2867	2886	2905	2924	2943	2962	2981	3000	3019	3038	3057	3076	3095	3114	3133	3152	3171	3190	3209	3228	3247	3266	3285	3304	3323	3342	3361	3380	3399	3418	3437	3456	3475	3494	3513	3532	3551	3570	3589	3608	3627	3646	3665	3684	3703	3722	3741	3760	3779	3798	3817	3836	3855	3874	3893	3912	3931	3950	3969	3988	4007	4026	4045	4064	4083	4102	4121	4140	4159	4178	4197	4216	4235	4254	4273	4292	4311	4330	4349	4368	4387	4406	4425	4444	4463	4482	4501	4520	4539	4558	4577	4596	4615	4634	4653	4672	4691	4710	4729	4748	4767	4786	4805	4824	4843	4862	4881	4900	4919	4938	4957	4976	4995	5014	5033	5052	5071	5090	5109	5128	5147	5166	5185	5204	5223	5242	5261	5280	5299	5318	5337	5356	5375	5394	5413	5432	5451	5470	5489	5508	5527	5546	5565	5584	5603	5622	5641	5660	5679	5698	5717	5736	5755	5774	5793	5812	5831	5850	5869	5888	5907	5926	5945	5964	5983	6002	6021	6040	6059	6078	6097	6116	6135	6154	6173	6192	6211	6230	6249	6268	6287	6306	6325	6344	6363	6382	6401	6420	6439	6458	6477	6496	6515	6534	6553	6572	6591	6610	6629	6648	6667	6686	6705	6724	6743	6762	6781	6800	6819	6838	6857	6876	6895	6914	6933	6952	6971	6990	7009	7028	7047	7066	7085	7104	7123	7142	7161	7180	7199	7218	7237	7256	7275	7294	7313	7332	7351	7370	7389	7408	7427	7446	7465	7484	7503	7522	7541	7560	7579	7598	7617	7636	7655	7674	7693	7712	7731	7750	7769	7788	7807	7826	7845	7864	7883	7902	7921	7940	7959	7978	7997	8016	8035	8054	8073	8092	8111	8130	8149	8168	8187	8206	8225	8244	8263	8282	8301	8320	8339	8358	8377	8396	8415	8434	8453	8472	8491	8510	8529	8548	8567	8586	8605	8624	8643	8662	8681	8700	8719	8738	8757	8776	8795	8814	8833	8852	8871	8890	8909	8928	8947	8966	8985	9004	9023	9042	9061	9080	9099	9118	9137	9156	9175	9194	9213	9232	9251	9270	9289	9308	9327	9346	9365	9384	9403	9422	9441	9460	9479	9498	9517	9536	9555	9574	9593	9612	9631	9650	9669	9688	9707	9726	9745	9764	9783	9802	9821	9840	9859	9878	9897	9916	9935	9954	9973	9992	10011	10030	10049	10068	10087	10106	10125	10144	10163	10182	10201	10220	10239	10258	10277	10296	10315	10334	10353	10372	10391	10410	10429	10448	10467	10486	10505	10524	10543	10562	10581	10600	10619	10638	10657	10676	10695	10714	10733	10752	10771	10790	10809	10828	10847	10866	10885	10904	10923	10942	10961	10980	10999	11018	11037	11056	11075	11094	11113	11132	11151	11170	11189	11208	11227	11246	11265	11284	11303	11322	11341	11360	11379	11398	11417	11436	11455	11474	11493	11512	11531	11550	11569	11588	11607	11626	11645	11664	11683	11702	11721	11740	11759	11778	11797	11816	11835	11854	11873	11892	11911	11930	11949	11968	11987	12006	12025	12044	12063	12082	12101	12120	12139	12158	12177	12196	12215	12234	12253	12272	12291	12310	12329	12348	12367	12386	12405	12424	12443	12462	12481	12500	12519	12538	12557	12576	12595	12614	12633	12652	12671	12690	12709	12728	12747	12766	12785	12804	12823	12842	12861	12880	12899	12918	12937	12956	12975	12994	13013	13032	13051	13070	13089	13108	13127	13146	13165	13184	13203	13222	13241	13260	13279	13298	13317	13336	13355	13374	13393	13412	13431	13450	13469	13488	13507	13526	13545	13564	13583	13602	13621	13640	13659	13678	13697	13716	13735	13754	13773	13792	13811	13830	13849	13868	13887	13906	13925	13944	13963	13982	14001	14020	14039	14058	14077	14096	14115	14134	14153	14172	14191	14210	14229	14248	14267	14286	14305	14324	14343	14362	14381	14400	14419	14438	14457	14476	14495	14514	14533	14552	14571	14590	14609	14628	14647	14666	14685	14704	14723	14742	14761	14780	14799	14818	14837	14856	14875	14894	14913	14932	14951	14970	14989	15008	15027	15046	15065	15084	15103	15122	15141	15160	15179	15198	15217	15236	15255	15274	15293	15312	15331	15350	15369	15388	15407	15426	15445	15464	15483	15502	15521	15540	15559	15578	15597	15616	15635	15654	15673	15692	15711	15730	15749	15768	15787	15806	15825	15844	15863	15882	15901	15920	15939	15958	15977	15996	16015	16034	16053	16072	16091	16110	16129	16148	16167	16186	16205	16224	16243	16262	16281	16300	16319	16338	16357	16376	16395	16414	16433	16452	16471	16490	16509	16528	16547	16566	16585	16604	16623	16642	16661	16680	16699	16718	16737	16756	16775	16794	16813	16832	16851	16870	16889	16908	16927	16946	16965	16984	17003	17022	17041	17060	17079	17098	17117	17136	17155	17174	17193	17212	17231	17250	17269	17288	17307	17326	17345	17364	17383	17402	17421	17440	17459	17478	17497	17516	17535	17554	17573	17592	17611	17630	17649	17668	17687	17706	17725	17744	17763	17782	17801	17820	17839	17858	17877	17896	17915	17934	17953	17972	17991	18010	18029	18048	18067	18086	18105	18124	18143	18162	18181	18200	18219	18238	18257	18276	18295	18314	18333	18352	18371	18390	18409	18428	18447	18466	18485	18504	18523	18542	18561	18580	18599	18618	18637	18656	18675	18694	18713	18732	18751	18770	18789	18808	18827	18846	18865	18884	18903	18922	18941	18960	18979	18998	19017	19036	19055	19074	19093	19112	19131	19150	19169	19188	19207	19226	19245	19264	19283	19302	19321	19340	19359	19378	19397	19416	19435	19454	19473	19492	19511	19530	19549	19568	19587	19606	19625	19644	19663	19682	19701	19720	19739	19758	19777	19796	19815	19834	19853	19872	19891	19910	19929	19948	19967	19986	20005	20024	20043	20062	20081	20100	20119	20138	20157	20176	20195	20214	20233	20252	20271	20290	20309	20328	20347	20366	20385	20404	20423	20442	20461	20480	20499	20518	20537	20556	20575	20594	20613	20632	20651	20670	20689	20708	20727	20746	20765	20784	20803	20822	20841	20860	20879	20898	20917	20936	20955	20974	20993	21012	21031	21050	21069	21088	21107	21126	21145	21164	21183	21202	21221	21240	21259	21278	21297	21316	21335	21354	21373	21392	21411	21430	21449	21468	21487	21506	21525	21544	21563	21582	21601	21620	21639	21658	21677	21696	21715	21734	21753	21772	21791	21810	21829	21848	21867	21886	21905	21924	21943	21962	21981	22000	22019	22038	22057	22076	22095	22114	22133	22152	22171	22190	22209	22228	22247	22266	22285	22304	22323	22342	22361	22380	22399	22418	22437	22456	22475	22494	22513	22532	22551	22570	22589	22608	22627	22646	22665	22684	22703	22722	22741	22760	22779	22798	22817	22836	22855	22874	22893	22912	22931	22950	22969	22988	23007	23026	23045	23064	23083	23102	23121	23140	23159	23178	23197	23216	23235	23254	23273	23292	23311	23330	23349	23368	23387	23406	23425	23444	23463	23482	23501	23520	23539	23558	23577	23596	23615	23634	23653	23672	23691	23710	23729	23748	23767	23786	23805	23824	23843	23862	23881	23900	23919	23938	23957	23976	23995	24014	24033	24052	24071	24090	24109	24128	24147	24166	24185	24204	24223	24242	24261	24280	24299	24318	24337	24356	24375	24394	24413	2443
--	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	------





**Fig. 5G**  
**HLA Intron 3 (Part IV)**

[illegible]



**Fig. 6**  
**HLA Class I Non Classicals DNA Sequence**

	3	6	9	12	18	24	30	36	42	48	54	60	66	72	78	84	90	96	102	108	116	120	126	132
CONSENSUS	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
E P213K	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
E 1.1-2	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
E 1.2-2	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
E 161	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
E EA	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
F	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
G S50740	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
G S63897	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
G TRP	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
G LA	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
G 21A	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
G 22A	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
G 3A	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
H	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
I	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
J	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
K	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
L	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
M	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
N	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
O	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
P	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
Q	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
R	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
S	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
T	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
U	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
V	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C
W	G	C	T	A	A	G	A	C	T	T	C	C	C	C	C									

[illegible]

**Exon 3 (Part II)**

[illegible]

15/15

Fig. 8

B-LCL Panel									
Dot Number	Name	HLA-A	HLA-B	HLA-C	Dot Number	Name	HLA-A	HLA-B	HLA-C
1	EA	A24	B7	Cw07	54	EK	A2	B44	Cw05
2	H2070782	A24	B14	Cw02, Cw05	55	H0301	A3	B14	Cw08
3	KAS116	A24	B51	Cw12	56	K05X	A2	B35	Cw12
4	JESTHOM	A2	B27	Cw01	57	TEM	A26	B38	Cw12
5	H0MC	A3	B27	Cw01	58	CHM	A2	B45	Cw16
6	WT100BIS	A11	B35	Cw04	59	SL2005	A2	B60	Cw03
7	DEM	A2	B57	Cw06	60	CB68	A1	B62	Cw03
8	D0208915	A25	B18	Cw12	61	J1227ABO	A2	B18	Cw07
9	KAS011	A1	B37	Cw06	62	MDV	A2	B38	Cw12
10	ANPAJ	A28	B53	Cw04	63	WT47	A32	B44	Cw05
11	B4181324	A1	B52	Cw12	64	ANGLA	A2	B62	Cw03
12	WTR076	A2	B57	Cw07	65	H02B	A3	B7	Cw07
13	SCBU	A3	B7	Cw07	66	TAB089	A2	B46	Cw01
14	H0AR	A26	B8	Cw07	67	HTB	A2	B27	Cw01
15	WT24	A2	B27	Cw02	68	B09	A2	B35	Cw04
16	WHL	A2	B52	Cw15	69	MADURA	A2	B60	Cw03
17	WTR	A3	B7	Cw07	70	LUY	A2	B51	Cw14, Cw00
18	LO081785	A3, A24	B18	Cw05	71	OLDA	A31	B62	Cw01
19	DUCAP	A30	B18	Cw05	72	SPACH	A31	B62	Cw01
20	QBL	A26	B18	Cw05	73	KT12	A24, A31	B51, B35	Cw04, Cw00
21	BSH	A68, A30	B42	Cw17	74	HID	A2	B60, B61	Cw03, Cw08
22	COX	A1	B8	Cw07	75	D08	A24	B60	Cw03
23	WAVY	A1	B8	Cw07	76	T7526	A2	B46	Cw01
24	KT17	A2, A11	B35, B62	Cw04, Cw03	77	T7527	A2	B46	Cw01
25	DEU	A31	B35	Cw04	78	PH0075	A3, A33	B65	Cw08
26	YAR	A26	B38	Cw12	79	LM0GS	A33	B14	Cw08
27	FF97387	A29	B44	Cw16	80	ISM	A3	B35	Cw04
28	PE117	A24	B60, B61	Cw03	81	EA	A3	B7	Cw07
29	WTS1	A23	B65	Cw08	82	H0104	A3	B7	Cw07
30	JHAP	A31	B51v	Cw15	83	LE2B	A3	B7	Cw07
31	BOLETH	A2	B62	Cw03	84	CALOGERO	A2	B61	Cw02
32	BSM	A2	B62	Cw03	85	EJ32B	A30	B18	Cw05
33	B014	A3	B7	Cw07	86	LO541265	A1	B8	Cw07
34	SAVC	A3	B7	Cw07	87	STEINLIN	A1	B8	Cw07
35	JMUSH	A32	B38	Cw12	88	PF04015	A1	B8	Cw07
36	SFO010	A2	B44	Cw05	89	BOB	A24	B51	Cw15
37	SNEIG007	A29	B61	Cw02	90	AMELLS	A2	B44	Cw05
38	BM16	A2	B18	Cw07	91	MLP	A2	B62	Cw01
39	JVM	A2	B18	Cw05	92	BM92	A25	B51	Cw01
40	BK15	A1	B49	Cw07	93	BER	A2	B13	Cw06
41	J0528239	A1	B35	Cw04	94	CP996	A2, A3	B14	Cw08
42	TISI	A24	B35	Cw04	95	WIN	A1	B57	Cw06
43	BK21	A1	B41	Cw17	96	LEP	A30	B13	Cw06
44	BRIP	A24	B51, B15	Cw00	97	BN7	A2, A3	B60	Cw03
45	TUBO	A2, A3	B51	Cw07, Cw15	98	MT14B	A31	B60	Cw03
46	BN	A2	B13	Cw06	99	LZL	A2	B62	Cw03
47	FLH	A3	B47	Cw06	100	OLL	A31	B62	Cw01
48	LBUP	A30	B13	Cw06	101	SPL	A31	B62	Cw01
49	IBW9	A33	B65	Cw08	102	ARBO	A3	B57	Cw06
50	MDU	A29	B44	Cw16	103	KT14	A24, A26	B51, B61	Cw08, Cw14
51	PITOUT	A29	B44	Cw16	105	FPAP	A1	B35	Cw04, Cw00
52	DEB	A2	B57	Cw06	106	MANIXA	A3	B50	Cw06
53	HCR	A33	B44	Cw14	107	LKT3	A24	B54	Cw01

SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/00362

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/68; C12P 19/34; C07H 21/04

US CL : 435/6, 91.2; 536/24.33

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.2; 536/24.33

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, BIOSIS, CAPLUS, EMBASE

search terms: HLA, typing, intron, amplification, PCR

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BLASCZYK et al. Complete subtyping of the HLA-A locus by sequence-specific amplification followed by direct sequencing or single-strand conformation polymorphism analysis. Tissue Antigens. April 1995, vol 46, pages 86-95. See pages 86-90.	1-16
X —, P Y	CEREB et al. Locus-specific amplification of HLA class I genes from genomic DNA: locus-specific sequences in the first and third introns of HLA-A, -B, and -C alleles. Tissue Antigens. December 1995, vol. 45, pages 1-11. See entire document.	1-3, 10, 14, 15, 17, 18, 22, 32, 33, 37, 38 ----- 1-29, 32-40

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	T	Inter document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	A*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* documents published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

09 MAY 1996

Date of mailing of the international search report

24 MAY 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

AMY ATZEL

Telephone No. (703) 308-0208

Form PCT/ISA/210 (second sheet)(July 1992)\*

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/00362

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, A	GERAGHTY et al. The HLA class I gene family includes at least six genes and twelve pseudogenes and gene fragments. J. Immunol. September 1992, vol. 149, pages 1934-46. Entire document.	1-29, 32-40
Y	LAWLOR et al. Ancient HLA genes from 7,500-year-old archaeological remains. Nature. February 1991, vol. 349, pages 785-788. See pages 785-787.	1-29, 32-40
Y, A	MALISSEN et al. Exon/intron organization and complete nucleotide sequence of an HLA gene. Proc. Natl. Acad. Sci. USA. February 1982, vol. 79, pages 893-97. Entire document.	1-29, 32-40
Y	JOSEPH et al. Classification of Mutations at the HLA-A locus by use of the polymerase chain reaction. Environmental and Molecular Mutagenesis. July 1993, vol. 22, pages 152-56. See page 153.	1-29, 32-40
Y	SUMMERS et al. HLA Class I Noncoding Nucleotide Sequences, 1992. Eur. J. Immunogenetics. Blackwell Scientific Publications. June 1993, vol. 20, pages 201-240. See pages 211-221.	1-29, 32-40

Form PCT/ISA/210 (continuation of second sheet)(July 1992)\*



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/00362

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 30 and 31  
because they relate to subject matter not required to be searched by this Authority, namely:  
Claims describe possible mental steps involved in selection of primers for amplification.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)\*